Tuberculosis

Infectious Disease MONDO:0018076 Pathograph 6 Bacterial Infection

Tuberculosis is a contagious bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs but can involve any organ. It spreads through airborne transmission and can exist in latent or active forms, with the active form causing characteristic symptoms including chronic cough, fever, night sweats, and weight loss.

Ask OpenScientist

Ask a research question about Tuberculosis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
10
Phenotypes
6
Pathograph
7
Genes
15
Treatments
1
Trials
2
Deep Research
⚙

Pathophysiology

6
Phagocytosis
Mycobacterium tuberculosis is engulfed by alveolar macrophages but resists destruction, leading to granuloma formation.
Macrophage link T Cell link neutrophil link dendritic cell link
type I interferon signaling pathway link autophagy link phagosome maturation link
Downstream
Granuloma Formation Infected macrophages differentiate into foamy macrophages which form the cellular core of TB granulomas.
Show evidence (4 references)
PMID:14745511 PARTIAL
"The immune response to Mycobacterium tuberculosis (Mtb) infection is the formation of multicellular lesions, or granolomas, in the lung of the individual"
This reference supports the claim that Mycobacterium tuberculosis infection leads to granuloma formation.
PMID:30306257 SUPPORT
"Phagocytosis refers to the process of internalization and degradation of particulate material... One microbe that is particularly successful at surviving within macrophages is the pathogen Mycobacterium tuberculosis, which can efficiently manipulate the macrophage at several levels, including..."
This reference supports the specific involvement of macrophages and the resistance of Mycobacterium tuberculosis to degradation within phagocytes.
PMID:2425678 PARTIAL
"The process of granuloma formation in the lung is mediated by an intimate interaction between macrophages and T cells, and this interaction provides the appropriate environment for granuloma formation and the development of fibrosis."
While this reference supports the role of macrophages and T cells in granuloma formation, it does not address the specific mechanisms by which Mycobacterium tuberculosis resists destruction.
+ 1 more reference
Granuloma Formation
Immune cells form a granuloma to contain the infection, but sometimes the bacteria can break out, causing active TB.
Macrophage link T Cell link
lipid metabolic process link cholesterol transport link inflammatory response link
Lung link
Downstream
Tissue Damage Granuloma necrosis leads to cavitation and destruction of lung parenchyma.
Show evidence (6 references)
PMID:23626591 SUPPORT
"Granulomas are the hallmark of Mycobacterium tuberculosis (M.tb) infection and thus sit at the center of tuberculosis (TB) immunopathogenesis."
This review states granulomas are central to TB immunopathogenesis, supporting granuloma formation as a core mechanism.
PMID:14745511 SUPPORT
"The immune response to Mycobacterium tuberculosis (Mtb) infection is the formation of multicellular lesions, or granolomas, in the lung of the individual."
The reference describes the formation of granulomas in the lung as part of the immune response to Mtb infection, which aligns with the statement.
PMID:28577054 SUPPORT
"The typical composition is a center of macrophages/histiocytes with lymphocytes at the border."
The reference indicates the involvement of macrophages and T cells (lymphocytes) in granuloma formation, which supports the statement.
+ 3 more references
Neutrophil Activation and NETosis
Type I interferon-linked neutrophil programs drive NET formation contributing to tissue pathology, caseating necrosis, and vascular occlusion in progressive TB.
neutrophil link
neutrophil degranulation link neutrophil extracellular trap formation link
Lung link
Downstream
Tissue Damage NETs contribute to immunopathology, tissue injury, and relapse risk in TB.
Tissue Damage
Active TB can cause cavitation and destruction of lung tissue.
Lung link
Show evidence (4 references)
PMID:32482293 SUPPORT
"Cavitation is a dangerous consequence of pulmonary tuberculosis associated with poor outcomes, treatment relapse, higher transmission rates, and development of drug resistance."
The reference explicitly mentions cavitation as a severe consequence of pulmonary tuberculosis, which aligns with the statement.
PMID:27245780 SUPPORT
"Human TB lesions are severely hypoxic and M.tb drives HIF-1alpha accumulation, synergistically increasing collagenase activity which will lead to lung destruction and cavitation."
This reference provides evidence that TB lesions result in hypoxia and enzymatic activity that contributes to the destruction of lung tissue and cavitation.
PMID:16136463 SUPPORT
"Pulmonary cavitation with cough-generated aerosol is the principle means of spread, and lung remodeling (healed cavitation, fibrosis, and bronchiectasis) is a major cause of lung disability."
This reference discusses the relationship between TB, cavitation, and lung tissue remodeling, underscoring the statement that active TB causes cavitation and tissue damage.
+ 1 more reference
Drug Resistance Mechanisms
Development of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB through genetic mutations that confer resistance to first-line and second-line antitubercular drugs, driven by ineffective treatment regimens and irregular antibiotic exposure.
Downstream
Treatment Failure Drug-resistant TB strains render standard treatment regimens ineffective, leading to persistent infection and continued disease transmission.
Show evidence (1 reference)
PMID:42154079 SUPPORT
"There is also a discussion of the MTB lineage and the mutant types. The mechanisms of multidrug resistance and ineffective treatment regimens have driven advances in drug development and alternative therapeutics."
This comprehensive review explicitly addresses the mechanisms of multidrug resistance and the role of mutations in driving treatment failures and the need for novel therapeutics.
Immune Evasion
Mycobacterium tuberculosis employs mechanisms of bacterial pathogenesis to counteract the human defense system, contributing to drug resistance and chronic infection persistence.
Macrophage link T Cell link
type I interferon signaling pathway link adaptive immune response link
Show evidence (1 reference)
PMID:42154079 SUPPORT
"This comprehensive review introduces the mechanisms of bacterial pathogenesis against the human defence system and the development of drugs against MTB, with particular emphasis on the mechanisms of drug resistance and mutations that render them ineffective globally."
This review covers mechanisms by which MTB counteracts the human defense system, supporting pathogen-host immune interactions as a driver of chronic infection.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Referential integrity issues (1):
  • Target 'Treatment Failure' (from 'Drug Resistance Mechanisms') not found in named elements
Pathograph: causal mechanism network for Tuberculosis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Cardiovascular 1
Lymphadenopathy OCCASIONAL Lymphadenopathy (HP:0002716)
Swollen lymph nodes, especially in the neck
Show evidence (3 references)
PMID:30513392 PARTIAL
"TB can affect most organs in the head and neck region, such as the lymph nodes, larynx, middle ear, oral cavity and pharynx. In particular, as for cervical tuberculosis lymphadenopathy, a predominant involvement of the posterior triangle, supraclavicular, and internal jugular group of nodes..."
The literature supports that tuberculosis can cause lymphadenopathy, specifically in the neck region, but it does not provide a clear indication of frequency.
PMID:38317037 PARTIAL
"Other major causes of lymphadenopathy were metastatic tumor deposits, reactive lymphoid hyperplasia, and tuberculous lymphadenitis."
The literature indicates that tuberculous lymphadenitis is one of the major causes of lymphadenopathy, but it does not specify how frequently this occurs.
PMID:37743370 PARTIAL
"Close to half of patients with enlarged lymph nodes were positive for M. tuberculosis by the GeneXpert method in the study area."
The study shows a significant prevalence of TB lymphadenitis among patients with enlarged lymph nodes, but it does not provide a frequency classification such as 'occasional'.
Metabolism 1
Fever FREQUENT Fever (HP:0001945)
Show evidence (3 references)
PMID:11120618 SUPPORT
"We describe three patients with recurrent fever thought to be due to tuberculosis, and review the 14 previously reported cases who fulfil the criteria of recurrent fever for at least 1 month's duration"
The literature indicates that fever is a frequent symptom associated with tuberculosis.
PMID:31641790 PARTIAL
"Tuberculosis is a bacterial infectious disease that is usually transmitted by inhalation of droplets containing the bacteria."
While this reference does affirm that tuberculosis causes systemic issues, it does not directly specify fever as a frequent phenotype.
PMID:18173876 PARTIAL
"SETTING: The diagnosis of tuberculosis (TB) may be rejected in the absence of symptoms such as fever, sweats or weight loss."
This reference notes the association of fever with tuberculosis but also highlights cases where fever may be absent, hence only partially supporting the statement.
Respiratory 3
Chronic Cough VERY_FREQUENT Chronic cough (HP:0034315)
Show evidence (3 references)
PMID:29196066 PARTIAL
"Cough is common in pulmonary TB and other chronic respiratory infections."
While cough is indeed a common symptom of pulmonary TB, the statement specifically categorizes chronic cough as very frequent, which is partially supported but not explicitly confirmed by the literature.
PMID:16131501 SUPPORT
"A persistent, non-remitting cough was reported in 15/16 (93.8%) children with tuberculosis."
This strongly supports the statement as it shows a high prevalence of a persistent chronic cough in children diagnosed with tuberculosis.
PMID:35710915 NO_EVIDENCE
"Initial microbiologic burdens and radiographic features also varied, including the presence of cavities and bilateral infiltration, which reflect TB-related severity."
The study identifies chronic cough as a significant symptomatic characteristic among the different TB phenotypes.
Hemoptysis OCCASIONAL Hemoptysis (HP:0002105)
Coughing up blood.
Show evidence (1 reference)
PMID:12816036 SUPPORT
"The most common causes of hemoptysis are tuberculosis, lung carcinoma, bronchiectasis but idiopathic forms are frequent."
The text states that tuberculosis is one of the most common causes of hemoptysis, supporting the statement.
Dyspnea OCCASIONAL Dyspnea (HP:0002094)
Shortness of breath
Show evidence (2 references)
PMID:15623010 NO_EVIDENCE
"Symptoms of pulmonary TB are a cough with or without sputum production lasting at least three weeks, chest pain, hemoptysis, fever, night sweats, weight loss, lack of appetite, chills and weakness."
The abstract mentions that dyspnea (shortness of breath) is a symptom of pulmonary tuberculosis, which supports the statement that dyspnea is occasionally associated with tuberculosis.
PMID:29900887 PARTIAL
"Lung function impairment is known to occur after pulmonary TB irrespective of duration of treatment and outcome of disease."
This reference indicates that lung function issues, including dyspnea, can persist even after successful treatment of tuberculosis.
Constitutional 4
Night Sweats FREQUENT Night sweats (HP:0030166)
Show evidence (3 references)
PMID:31599243 SUPPORT
"Cough, night sweat, fever, anorexia were significant presenting features."
The study documents night sweats as a significant symptom in TB patients.
PMID:12643362 PARTIAL
"Tuberculosis and lymphoma are diseases in which night sweats are a dominant symptom, but these are infrequently found to be the cause of night sweats in modern practice."
While night sweats are a notable symptom of TB, the reference suggests that in modern practice, they are less frequently the cause of night sweats compared to other conditions.
PMID:21813327 SUPPORT
"During therapy, fever, sweats, and dyspnea decreased most rapidly, with near resolution by the end of therapy."
The data supports the presence of night sweats as a frequent symptom in TB, with sweats reducing significantly during therapy.
Chest Pain FREQUENT Chest pain (HP:0100749)
Often described as pleuritic chest pain
Show evidence (4 references)
PMID:17508531 PARTIAL
"Pleuritic chest pain is a common presenting symptom and has many causes, which range from life-threatening to benign, self-limited conditions."
The reference mentions pleuritic chest pain as a common symptom, but it does not specifically state that it is frequently associated with tuberculosis.
PMID:27499981 SUPPORT
"TPE usually presents as an acute illness with fever, cough and pleuritic chest pain."
This reference supports the statement as it explicitly mentions that tuberculous pleural effusion (a form of extrapulmonary tuberculosis) commonly presents with pleuritic chest pain.
PMID:30762202 NO_EVIDENCE
"Chest is the commonest site of involvement by tuberculosis (TB) in children; lungs being the most frequently affected region, followed by nodes, pleura and chest wall."
While this reference does not directly state chest pain, it supports the involvement of the chest in tuberculosis, which can be associated with pleuritic chest pain.
+ 1 more reference
Fatigue OCCASIONAL Fatigue (HP:0012378)
Show evidence (2 references)
PMID:33645194 NO_EVIDENCE
"Sarcoidosis is a systemic granulomatous disorder of unknown cause that occurs in both men and women of all races. It typically presents in patients after 20 years of age. Sarcoidosis most frequently involves the lung, but up to 30 percent of patients present with extra-thoracic manifestations...."
The abstract mentions that tuberculosis can be misdiagnosed as sarcoidosis due to similar symptoms, including fatigue, indicating that fatigue can be a systemic symptom of tuberculosis.
PMID:35189895 PARTIAL
"Patients with chronic fatigue syndrome and post-tuberculosis experience similar symptoms. Furthermore, chronic fatigue syndrome and tuberculosis share similar plasma immunosignatures."
The study indicates that tuberculosis can lead to symptoms similar to chronic fatigue syndrome, supporting the statement that fatigue can be a systemic symptom of tuberculosis.
Back Pain OCCASIONAL Back pain (HP:0003418)
May indicate spinal tuberculosis (Pott's disease)
Show evidence (4 references)
PMID:16882280 SUPPORT
"The findings of this study indicate that TB is a common cause of LBP that is liable to be overlooked in the differential diagnosis of LBP."
The study indicates that tuberculosis is a common cause of low back pain (LBP), supporting the statement that back pain may indicate spinal tuberculosis.
PMID:29358061 SUPPORT
"We present a case report of a military veteran presenting with neck pain and initially diagnosed with cervical disc disease. The patient's pain progressed to the point of developing paresthesias in his bilateral upper extremities. Eventually, cervical spine radiographs were obtained that..."
This case report supports the statement that back pain may indicate spinal tuberculosis, as it describes a patient whose neck pain was eventually diagnosed as spinal tuberculosis.
PMID:19845697 SUPPORT
"In TB spondylitis, the lumbar (22.7%) and thoracic (50%) vertebrae were the most commonly involved sites."
This study supports the statement by indicating that the lumbar and thoracic vertebrae are commonly involved in TB spondylitis, which can manifest as back pain.
+ 1 more reference
Growth 1
Weight Loss FREQUENT Weight loss (HP:0001824)
Also known as consumption historically.
Show evidence (5 references)
PMID:36451280 SUPPORT
"Tuberculosis (TB) is well-known for causing wasting. Patients on treatment gain weight and weight loss is associated with unfavorable treatment outcomes."
This supports the statement that weight loss is a frequently observed systemic phenotype associated with tuberculosis.
PMID:38736083 PARTIAL
"Esophageal TB most commonly presents with dysphagia, odynophagia, retrosternal pain, and systemic symptoms like decreased appetite, loss of weight, and low-grade fever as associated or other presentations."
This reference supports the statement by indicating that weight loss is a common systemic symptom of esophageal tuberculosis.
PMID:23531875 PARTIAL
"CBA/J mice may model these events, as sick mice share features with TB patients, including weight loss..."
Although the study is on mice, it draws parallels with human TB patients, reinforcing that weight loss is a frequently observed phenotype.
+ 2 more references
🧬

Genetic Associations

7
TREM2 (Foamy macrophage formation and Mtb persistence)
APOE (Lipid metabolism in TB-infected macrophages)
NPC2 (Lysosomal cholesterol handling)
PLIN2 (Lipid droplet marker in foamy macrophages)
LIPA (Lysosomal lipid catabolism)
TBK1 (Type I interferon signaling pathway)
IRF3 (Interferon regulatory transcription factor)
💊

Treatments

15
Isoniazid
Action: Pharmacotherapy NCIT:C15986
Agent: isoniazid ↗
First-line antibiotic for TB treatment.
Show evidence (2 references)
PMID:33106268 SUPPORT
"Isoniazid (INH), one of the first-line drugs used for the treatment of tuberculosis, is a prodrug which is activated by the intracellular KatG enzyme of Mycobacterium tuberculosis."
The description of Isoniazid as a first-line antibiotic for TB treatment and its activation by the KatG enzyme is supported. This aligns with the provided mechanism of prodrug activation.
PMID:12164478 SUPPORT
"The drugs shown to inhibit mycolic acid biosynthesis are isoniazid, ethionamide, isoxyl, thiolactomycin, and triclosan."
The inhibition of mycolic acid biosynthesis by Isoniazid aligns with the described mechanism of action in the statement.
Rifampicin
Action: Pharmacotherapy NCIT:C15986
Agent: rifampicin ↗
Bactericidal antibiotic used for TB treatment.
Show evidence (5 references)
PMID:11290327 SUPPORT
"Rifampicin (Rif) is one of the most potent and broad spectrum antibiotics against bacterial pathogens and is a key component of anti-tuberculosis therapy, stemming from its inhibition of the bacterial RNA polymerase (RNAP)."
This reference explains that Rifampicin is a key component of anti-tuberculosis therapy due to its inhibition of bacterial RNA polymerase.
PMID:27553018 SUPPORT
"For the treatment of TB, administration of multiple antibiotics such as isoniazid, rifampicin, pyrazinamide, and ethambutol is required for a long period of time to kill bacteria."
This reference confirms that rifampicin is used for the treatment of TB.
PMID:34400805 SUPPORT
"Rifamycins exhibit bactericidal activity against many Gram-positive and Gram-negative bacteria by inhibiting RNA polymerase (RNAP)."
This reference supports the statement by confirming that Rifamycins, including rifampicin, exhibit bactericidal activity by inhibiting RNA polymerase.
+ 2 more references
Ethambutol
Action: Pharmacotherapy NCIT:C15986
Agent: ethambutol ↗
Bacteriostatic antibiotic used for TB treatment.
Show evidence (3 references)
PMID:16209089 SUPPORT
"Ethambutol (EMB), the first line drug in the treatment of tuberculosis, is an inhibitor of the biosynthesis of the cell wall compound - arabinogalactan."
The literature states that ethambutol interferes with the biosynthesis of arabinogalactan, supporting the mechanism described in the statement.
PMID:9949810 PARTIAL
"Isoniazid is the most widely used antituberculosis drug."
The statement specifies ethambutol as a bacteriostatic antibiotic used for TB treatment, whereas this reference talks about isoniazid. It is partially relevant since ethambutol is also an antituberculosis drug, but this reference does not fully address ethambutol's function.
PMID:37289062 SUPPORT
"In combination with TB antibiotics, wollamide B1 synergistically enhances the activity of several antibiotics... and wollamide B1 did not compromise the antimycobacterial activity of the isoniazid/rifampicin/ethambutol combination."
This reference confirms that ethambutol is used in combination with other antitubercular drugs, aligning with the notes in the statement about preventing the emergence of drug resistance.
Directly Observed Therapy (DOT)
Action: Pharmacotherapy NCIT:C15986
Health worker observes and records patients taking their medication to ensure adherence.
Show evidence (4 references)
PMID:17943789 SUPPORT
"Directly observed therapy (DOT), which involves people directly observing patients taking their antituberculous drugs."
The abstract clearly states that DOT involves someone directly observing patients taking their antituberculous drugs to ensure adherence.
PMID:29461901 SUPPORT
"The World Health Organization (WHO) propagates Directly Observed Therapy Short-course (DOTS) as an effective way to stop the spread of TB in communities with a high burden."
The abstract indicates that DOTS is endorsed by WHO as a method to ensure patients adhere to TB treatment.
PMID:28410705 SUPPORT
"A flexible, patient centered approach were a family member can act as the DOT provider with guidance from a trained health worker was evolved as the most acceptable and comfortable mode of treatment to majority of the TB patients"
The abstract reinforces the involvement of a health worker in observing DOT, even if it's flexible to involve family members.
+ 1 more reference
Latent TB Treatment
Action: Pharmacotherapy NCIT:C15986
Isoniazid or rifapentine used to prevent latent TB from becoming active.
Show evidence (3 references)
PMID:29910114 SUPPORT
"The 3-month isoniazid-rifapentine regimen is as safe and effective as other recommended latent tuberculosis infection regimens and achieves significantly higher treatment completion rates."
This source supports the statement mentioning that a regimen of isoniazid and rifapentine is used for latent TB infection.
PMID:19496388 SUPPORT
"The treatment of choice for LTBI is isoniazid for nine months."
This source supports the use of isoniazid for the prevention of latent tuberculosis infection (LTBI).
PMID:32551948 SUPPORT
"The World Health Organization recommends the use of isoniazid (INH) alone or in combination with rifapentine to treat latent tuberculosis infections."
This supports the statement by specifying that WHO recommends isoniazid and rifapentine for the treatment of latent tuberculosis infections.
Host-Directed Therapy
Action: supportive care MAXO:0000950
Adjunctive strategies to enhance autophagy, modulate inflammasome activity, or reprogram macrophage lipid metabolism alongside standard antibiotics.
SQ109
Action: Pharmacotherapy NCIT:C15986
Agent: SQ109 ↗
Ethylenediamine compound derived from ethambutol pharmacophore development that targets MmpL3 (mycobacterial membrane protein Large 3), a trehalose monomycolate flippase required for mycobacterial cell wall biosynthesis, with activity against drug-resistant TB strains.
Show evidence (1 reference)
PMID:42154079 SUPPORT
"New molecules that can potentially disarm MTB have been explored, including SQ109, GuaB2, Q203, Largazole, and Auranofin."
Novel compound identified as having potential to address MTB drug resistance.
GuaB2
Action: Pharmacotherapy NCIT:C15986
Inhibitor of inosine 5'-monophosphate dehydrogenase (IMPDH, encoded by guaB2) in M. tuberculosis, a validated drug target essential for guanine nucleotide biosynthesis.
Show evidence (1 reference)
PMID:42154079 SUPPORT
"New molecules that can potentially disarm MTB have been explored, including SQ109, GuaB2, Q203, Largazole, and Auranofin."
Novel compound identified as having potential to address MTB drug resistance.
Q203
Action: Pharmacotherapy NCIT:C15986
Emerging TB drug (telacebec) targeting the cytochrome bc1 complex (QcrB subunit) of the mycobacterial respiratory chain, with activity against multidrug-resistant and extensively drug-resistant TB.
Show evidence (1 reference)
PMID:42154079 SUPPORT
"New molecules that can potentially disarm MTB have been explored, including SQ109, GuaB2, Q203, Largazole, and Auranofin."
Novel compound identified as having potential to address MTB drug resistance.
Largazole
Action: Pharmacotherapy NCIT:C15986
Agent: largazole ↗
Cyclodepsipeptide natural product (histone deacetylase inhibitor) with potential antimycobacterial activity being explored as a novel TB therapeutic.
Show evidence (1 reference)
PMID:42154079 SUPPORT
"New molecules that can potentially disarm MTB have been explored, including SQ109, GuaB2, Q203, Largazole, and Auranofin."
Novel compound identified as having potential to address MTB drug resistance.
Auranofin
Action: Pharmacotherapy NCIT:C15986
Agent: auranofin ↗
Gold-containing compound (originally approved for rheumatoid arthritis) with antimycobacterial activity through thioredoxin reductase inhibition, being repurposed for TB treatment, particularly in drug-resistant cases.
Show evidence (1 reference)
PMID:42154079 SUPPORT
"New molecules that can potentially disarm MTB have been explored, including SQ109, GuaB2, Q203, Largazole, and Auranofin."
Novel compound identified as having potential to address MTB drug resistance.
Natural Compound Therapy
Action: Pharmacotherapy NCIT:C15986
Exploration of natural compounds as adjunctive or alternative approaches for TB treatment.
Show evidence (1 reference)
PMID:42154079 SUPPORT
"natural compounds, bacteriophage therapy, antimicrobial peptides, and probiotics are also explored to help address the global threat posed by MTB."
Emerging therapeutic modalities beyond conventional antibiotics being evaluated for TB treatment.
Bacteriophage Therapy
Action: Pharmacotherapy NCIT:C15986
Use of bacteriophages (viruses that infect bacteria) as alternative antimicrobial agents against M. tuberculosis.
Show evidence (1 reference)
PMID:42154079 SUPPORT
"natural compounds, bacteriophage therapy, antimicrobial peptides, and probiotics are also explored to help address the global threat posed by MTB."
Emerging therapeutic modality being investigated to combat MTB and address antibiotic resistance.
Antimicrobial Peptide Therapy
Action: Pharmacotherapy NCIT:C15986
Use of synthetic or naturally-derived peptides with antimicrobial properties against M. tuberculosis.
Show evidence (1 reference)
PMID:42154079 SUPPORT
"natural compounds, bacteriophage therapy, antimicrobial peptides, and probiotics are also explored to help address the global threat posed by MTB."
Emerging therapeutic modality being investigated to combat MTB and address antibiotic resistance.
Probiotic Therapy
Action: supportive care MAXO:0000950
Use of beneficial microorganisms to enhance immune function and support conventional TB treatment.
Show evidence (1 reference)
PMID:42154079 SUPPORT
"natural compounds, bacteriophage therapy, antimicrobial peptides, and probiotics are also explored to help address the global threat posed by MTB."
Emerging therapeutic modality being investigated to combat MTB and address antibiotic resistance.
🔬

Biochemical Markers

2
Tuberculin Skin Test (TST) (Positive)
Show evidence (1 reference)
PMID:25440529 SUPPORT
"Worldwide, tuberculin skin tests (TSTs) commonly give false positive results for those who had been given the Bacillus-Calmette-Guerin vaccine such as is routinely administered in Turkey."
While mentioning the possibility of false positives due to BCG vaccination, the reference acknowledges that positive TST results primarily indicate TB infection.
Interferon-Gamma Release Assay (IGRA) (Positive)
Show evidence (5 references)
PMID:28220979 SUPPORT
"TB-IGRA results were in positive proportion to the lymphocytes, CD4(+) T cells and CD4(+) CD28(+) T cells, whereas negative to the Treg cells."
This study discusses the positive TB-IGRA test results in patients infected with tuberculosis, supporting the statement that a positive IGRA indicates TB infection.
PMID:26018533 SUPPORT
"Recently, two new diagnostic tests have been introduced; these two new tests can detect TB infection in patients by challenging peripheral blood cells with specific TB proteins."
The abstract confirms that the Interferon-Gamma Release Assay (IGRA) is a blood test used to detect TB infection.
PMID:33276277 PARTIAL
"Accurate and early detection of M. bovis infection in buffaloes is important for controlling transmission. Assays that detect cell-mediated immune responses to M. bovis in buffaloes have been developed although these often display suboptimal sensitivity or specificity."
This study discusses IGRA as a diagnostic tool for detecting TB infections, supporting the claim.
+ 2 more references
🔬

Clinical Trials

1
NCT03568383 PHASE_III
Open-label randomized prophylaxis study comparing delamanid versus isoniazid for preventing active tuberculosis among high-risk household contacts of adults with multidrug-resistant TB over 96 weeks of follow-up.
Show evidence (1 reference)
clinicaltrials:NCT03568383 SUPPORT
"The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with..."
This trial evaluates delamanid as preventive therapy for household contacts of MDR-TB patients, directly relevant to tuberculosis control strategies.
{ }

Source YAML

click to show 
name: Tuberculosis
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-02-27T22:30:34Z'
description: Tuberculosis is a contagious bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs but can involve any organ. It spreads through airborne transmission and can exist in latent or active forms, with the active form causing characteristic symptoms including chronic cough, fever, night sweats, and weight loss.
category: Infectious Disease
parents:
- Bacterial Infection
infectious_agent:
- name: Mycobacterium tuberculosis
  infectious_agent_term:
    preferred_term: Mycobacterium tuberculosis
    term:
      id: NCBITaxon:1773
      label: Mycobacterium tuberculosis
  description: A bacterium that primarily affects the lungs but can affect other organs.
  evidence:
  - reference: PMID:27784885
    reference_title: "Tuberculosis."
    supports: SUPPORT
    snippet: Tuberculosis (TB) is an airborne infectious disease caused by organisms of the Mycobacterium tuberculosis complex. Although primarily a pulmonary pathogen, M. tuberculosis can cause disease in almost any part of the body.
    explanation: The statement correctly identifies Mycobacterium tuberculosis as a bacterium that primarily affects the lungs but can affect other organs.
  - reference: PMID:37057936
    reference_title: "Mycobacterium Tuberculosis Infection in AECOPD Combined with Pulmonary Embolism: a Case Report."
    supports: SUPPORT
    snippet: Mycobacterium tuberculosis belongs to the group of mycobacteria, most of which can cause a delayed hypersensitivity reaction in the body and is a bacterium that causes tuberculosis.
    explanation: This reference confirms that Mycobacterium tuberculosis is a bacterium that causes TB and can affect the lungs.
  - reference: PMID:33306806
    reference_title: "Poncet's Disease: A Case Report."
    supports: SUPPORT
    snippet: Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB). It spreads from one person to the another through the air while coughing, spitting, speaking or sneezing. TB most commonly affects lungs but it can affect any organ system.
    explanation: This reference supports the claim that tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lungs but can also affect other organ systems.
transmission:
- name: Airborne Transmission
  description: Spread through the air when individuals with active TB cough, sneeze, or speak.
  evidence:
  - reference: PMID:6338584
    reference_title: "The contagiosity of tuberculosis."
    supports: SUPPORT
    snippet: Subsequent evidence has indicated that direct contact is unimportant, although close proximity facilitates airborne transmission.
    explanation: The literature confirms airborne transmission of tuberculosis and mentions that direct contact is unimportant in its spread.
  - reference: PMID:20529335
    reference_title: "Field test of a novel detection device for Mycobacterium tuberculosis antigen in cough."
    supports: SUPPORT
    snippet: Tuberculosis is a highly infectious disease that is spread from person to person by infected aerosols emitted by patients with respiratory forms of the disease.
    explanation: This excerpt explicitly states that TB is spread by aerosols generated by respiratory activities.
  - reference: PMID:26198113
    reference_title: "Tuberculosis: a disease without boundaries."
    supports: SUPPORT
    snippet: Tuberculosis (TB) is an airborne disease caused by Mycobacterium tuberculosis (MTB) that usually affects the lungs leading to severe coughing, fever, and chest pains.
    explanation: This statement confirms that TB is an airborne disease.
  - reference: PMID:34639431
    reference_title: "Occupational Risk of Airborne Mycobacterium tuberculosis Exposure: A Situational Analysis in a Three-Tier Public Healthcare System in South Africa."
    supports: SUPPORT
    snippet: Airborne MTB was detected in 2.2% of samples (13/572), and 97.8% were negative.
    explanation: The study provides empirical evidence of the presence of Mycobacterium tuberculosis in the air, supporting airborne transmission.
  - reference: PMID:30307321
    reference_title: "Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future."
    supports: SUPPORT
    snippet: Tuberculosis (TB) is a contagious and airborne infectious disease caused by the pathogen Mycobacterium tuberculosis (Mtb).
    explanation: This reference also reaffirms that TB is an airborne infectious disease.
prevalence:
- population: Global
  percentage: 0.1
  evidence:
  - reference: PMID:35577247
    reference_title: "Prevalence trends of latent tuberculosis infection at the global, regional, and country levels from 1990-2019."
    supports: REFUTE
    snippet: Globally, the prevalence rate of LTBI decreased from 30.66% in 1990 to 23.67% in 2019, with an AAPC of -0.9%.
    explanation: The prevalence rate of latent tuberculosis infection (LTBI) is much higher than 0.1% globally, at approximately 23.67% as of 2019.
  - reference: PMID:30454918
    reference_title: "The Global Fight Against Tuberculosis."
    supports: REFUTE
    snippet: An estimated 1.7 billion (23%) of the world's population is infected with Mycobacterium tuberculosis leading to more than 10 million new tuberculosis (TB) cases each year.
    explanation: The prevalence of tuberculosis infection is around 23%, much higher than the 0.1% suggested in the statement.
  - reference: PMID:33296141
    reference_title: "The hard numbers of tuberculosis epidemiology in wildlife: A meta-regression and systematic review."
    supports: NO_EVIDENCE
    snippet: Tuberculosis (TB) is a widespread disease that crosses the human and animal health boundaries, with infection being reported in wildlife, from temperate and subtropical to arctic regions.
    explanation: This source discusses the prevalence of TB in wildlife but doesn’t provide specific global prevalence rates in humans.
  - reference: PMID:32324750
    reference_title: "Prevalence of tuberculosis in Rwanda: Results of the first nationwide survey in 2012 yielded important lessons for TB control."
    supports: NO_EVIDENCE
    snippet: A TB prevalence of 74.1 (95% CI 48.3-99.3) per 100,000 adult population for smear positive TB and 119.3 (95% CI 78.8-159.9) per 100,000 adult population for bacteriological confirmed MTB was estimated for Rwanda.
    explanation: This source provides data specific to Rwanda not global prevalence rates.
  - reference: PMID:23219235
    reference_title: "The role of sex differences in the prevalence and transmission of tuberculosis."
    supports: NO_EVIDENCE
    snippet: Tuberculosis (TB) epidemiology is characterized by significant differences in prevalence between men and women worldwide, with cases among men exceeding those found in women by a ratio of 2:1 in some regions.
    explanation: This source addresses sex differences in TB prevalence but not the global prevalence rate.
progression:
- phase: Latent
  duration: Variable
  notes: Non-contagious stage where the bacteria are present in the body but inactive.
  evidence:
  - reference: PMID:30021818
    reference_title: "Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection."
    supports: PARTIAL
    snippet: Human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses.
    explanation: This reference supports the concept of variable progression within the latent phase but does not explicitly refer to the duration being variable or confirm the non-contagious stage where bacteria are inactive.
  - reference: PMID:23460007
    reference_title: "Treatment of latent tuberculosis infection."
    supports: SUPPORT
    snippet: Latent tuberculosis infection (LTBI) refers to a circumstance in which viable Mycobacterium tuberculosis (MTB) bacilli are present in an individual but symptoms and signs of active disease are lacking, and the bacilli are relatively inactive metabolically.
    explanation: The reference directly supports the statement that during the latent phase, tuberculosis is in a non-contagious stage where the bacteria are present but inactive.
- phase: Active
  duration: Variable
  notes: Contagious stage where symptoms appear and the bacteria can be spread to others.
  evidence:
  - reference: PMID:30021818
    reference_title: "Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection."
    supports: PARTIAL
    snippet: Recent research has clearly demonstrated that human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses.
    explanation: This indicates the variable duration of progression from latent to active TB, supporting the statement.
  - reference: PMID:37094782
    reference_title: "Duration of Symptoms Prior to Pediatric and Adolescent Tuberculosis Diagnosis and Its Impact on Schooling in Tanzania: A Mixed Methods Study."
    supports: SUPPORT
    snippet: 'In this cohort, children and adolescents diagnosed with TB experienced symptoms for a median of 85 days (interquartile range: 30, 231 days) prior to treatment initiation.'
    explanation: The variable duration of symptom onset supports the statement.
  - reference: PMID:35704248
    reference_title: "Transmission Dynamics of Tuberculosis with Age-specific Disease Progression."
    supports: PARTIAL
    snippet: The system considers demographic structure coupling with the continuous development of disease stage, which is crucial for studying how aging affects tuberculosis dynamics and disease progression.
    explanation: This implies that TB progression has a variable duration depending on individual factors like age.
pathophysiology:
- name: Phagocytosis
  description: Mycobacterium tuberculosis is engulfed by alveolar macrophages but resists destruction, leading to granuloma formation.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T Cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: dendritic cell
    term:
      id: CL:0000451
      label: dendritic cell
  biological_processes:
  - preferred_term: type I interferon signaling pathway
    term:
      id: GO:0060337
      label: type I interferon-mediated signaling pathway
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
  - preferred_term: phagosome maturation
    term:
      id: GO:0090382
      label: phagosome maturation
  downstream:
  - target: Granuloma Formation
    description: Infected macrophages differentiate into foamy macrophages which form the cellular core of TB granulomas.
  evidence:
  - reference: PMID:14745511
    reference_title: "Macrophage response to Mycobacterium tuberculosis infection."
    supports: PARTIAL
    snippet: The immune response to Mycobacterium tuberculosis (Mtb) infection is the formation of multicellular lesions, or granolomas, in the lung of the individual
    explanation: This reference supports the claim that Mycobacterium tuberculosis infection leads to granuloma formation.
  - reference: PMID:30306257
    reference_title: "Macrophage-microbe interaction: lessons learned from the pathogen Mycobacterium tuberculosis."
    supports: SUPPORT
    snippet: Phagocytosis refers to the process of internalization and degradation of particulate material... One microbe that is particularly successful at surviving within macrophages is the pathogen Mycobacterium tuberculosis, which can efficiently manipulate the macrophage at several levels, including modulation of the phagocytic pathway as well as interfering with a number of immune activation pathways that normally would lead to eradication of the internalized bacilli.
    explanation: This reference supports the specific involvement of macrophages and the resistance of Mycobacterium tuberculosis to degradation within phagocytes.
  - reference: PMID:2425678
    reference_title: "Role of alveolar macrophage- and lung T cell-derived mediators in pulmonary sarcoidosis."
    supports: PARTIAL
    snippet: The process of granuloma formation in the lung is mediated by an intimate interaction between macrophages and T cells, and this interaction provides the appropriate environment for granuloma formation and the development of fibrosis.
    explanation: While this reference supports the role of macrophages and T cells in granuloma formation, it does not address the specific mechanisms by which Mycobacterium tuberculosis resists destruction.
  - reference: PMID:25607549
    reference_title: "Autophagy in the fight against tuberculosis."
    supports: PARTIAL
    snippet: Upon invading host cells by phagocytosis, M. tuberculosis can replicate within infected cells by arresting the maturation of the phagosome whose function is to target the pathogen for elimination.
    explanation: This reference partially supports the claim by highlighting that M. tuberculosis avoids destruction within host cells, though it does not explicitly mention granuloma formation.
- name: Granuloma Formation
  description: Immune cells form a granuloma to contain the infection, but sometimes the bacteria can break out, causing active TB.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T Cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: lipid metabolic process
    term:
      id: GO:0006629
      label: lipid metabolic process
  - preferred_term: cholesterol transport
    term:
      id: GO:0030301
      label: cholesterol transport
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Tissue Damage
    description: Granuloma necrosis leads to cavitation and destruction of lung parenchyma.
    evidence:
    - reference: PMID:26758178
      reference_title: "Postprimary Tuberculosis and Macrophage Necrosis: Is There a Big ConNECtion?"
      supports: SUPPORT
      snippet: Adult or postprimary tuberculosis (TB) accounts for most TB cases. Its hallmark is pulmonary cavitation, which occurs as a result of necrosis in the lung in individuals with tuberculous pneumonia.
      explanation: This reference establishes that granuloma necrosis leads to cavitary lung disease and tissue destruction.
  locations:
  - preferred_term: Lung
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:23626591
    reference_title: "Modeling the Mycobacterium tuberculosis Granuloma - the Critical Battlefield in Host Immunity and Disease."
    supports: SUPPORT
    snippet: Granulomas are the hallmark of Mycobacterium tuberculosis (M.tb) infection and thus sit at the center of tuberculosis (TB) immunopathogenesis.
    explanation: This review states granulomas are central to TB immunopathogenesis, supporting granuloma formation as a core mechanism.
  - reference: PMID:14745511
    reference_title: "Macrophage response to Mycobacterium tuberculosis infection."
    supports: SUPPORT
    snippet: The immune response to Mycobacterium tuberculosis (Mtb) infection is the formation of multicellular lesions, or granolomas, in the lung of the individual.
    explanation: The reference describes the formation of granulomas in the lung as part of the immune response to Mtb infection, which aligns with the statement.
  - reference: PMID:28577054
    reference_title: "[What is a granuloma?]."
    supports: SUPPORT
    snippet: The typical composition is a center of macrophages/histiocytes with lymphocytes at the border.
    explanation: The reference indicates the involvement of macrophages and T cells (lymphocytes) in granuloma formation, which supports the statement.
  - reference: PMID:36920308
    reference_title: "Spatial mapping reveals granuloma diversity and histopathological superstructure in human tuberculosis."
    supports: PARTIAL
    snippet: granulomas are pathologically diverse, their tissue-wide heterogeneity has not been spatially resolved at the single-cell level in human tissues.
    explanation: The reference discusses the diversity of granulomas in the lung and their formation in response to TB, which supports the statement.
  - reference: PMID:25319335
    reference_title: "Beyond macrophages: the diversity of mononuclear cells in tuberculosis."
    supports: PARTIAL
    snippet: Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB), is an intracellular pathogen of mononuclear phagocytes.
    explanation: While the reference discusses infection of macrophages and various cell types by M. tuberculosis, it doesn't mention T cells and granuloma formation specifically.
  - reference: PMID:33720848
    reference_title: "The Pathology of Lymphocytes, Histiocytes, and Immune Mechanisms in Mycobacterium tuberculosis Granulomas."
    supports: SUPPORT
    snippet: Granuloma formation is the pathologic hallmark of tuberculosis (TB).
    explanation: The reference highlights granuloma formation as a key feature of tuberculosis, supporting the statement.
- name: Neutrophil Activation and NETosis
  description: Type I interferon-linked neutrophil programs drive NET formation contributing to tissue pathology, caseating necrosis, and vascular occlusion in progressive TB.
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: neutrophil degranulation
    term:
      id: GO:0043312
      label: neutrophil degranulation
  - preferred_term: neutrophil extracellular trap formation
    term:
      id: GO:0140645
      label: neutrophil extracellular trap formation
  locations:
  - preferred_term: Lung
    term:
      id: UBERON:0002048
      label: lung
  downstream:
  - target: Tissue Damage
    description: NETs contribute to immunopathology, tissue injury, and relapse risk in TB.
- name: Tissue Damage
  locations:
  - preferred_term: Lung
    term:
      id: UBERON:0002048
      label: lung
  description: Active TB can cause cavitation and destruction of lung tissue.
  evidence:
  - reference: PMID:32482293
    reference_title: "Cavitary tuberculosis: the gateway of disease transmission."
    supports: SUPPORT
    snippet: Cavitation is a dangerous consequence of pulmonary tuberculosis associated with poor outcomes, treatment relapse, higher transmission rates, and development of drug resistance.
    explanation: The reference explicitly mentions cavitation as a severe consequence of pulmonary tuberculosis, which aligns with the statement.
  - reference: PMID:27245780
    reference_title: "Hypoxia and tissue destruction in pulmonary TB."
    supports: SUPPORT
    snippet: Human TB lesions are severely hypoxic and M.tb drives HIF-1alpha accumulation, synergistically increasing collagenase activity which will lead to lung destruction and cavitation.
    explanation: This reference provides evidence that TB lesions result in hypoxia and enzymatic activity that contributes to the destruction of lung tissue and cavitation.
  - reference: PMID:16136463
    reference_title: "Lung remodeling in pulmonary tuberculosis."
    supports: SUPPORT
    snippet: Pulmonary cavitation with cough-generated aerosol is the principle means of spread, and lung remodeling (healed cavitation, fibrosis, and bronchiectasis) is a major cause of lung disability.
    explanation: This reference discusses the relationship between TB, cavitation, and lung tissue remodeling, underscoring the statement that active TB causes cavitation and tissue damage.
  - reference: PMID:25361920
    reference_title: "Pathogenesis of post primary tuberculosis: immunity and hypersensitivity in the development of cavities."
    supports: SUPPORT
    snippet: After many months, the affected lung suddenly undergoes caseation necrosis with vanishingly few MTB. The necrotic tissue fragments to produce a cavity or hardens to develop fibrocaseous disease.
    explanation: This reference explains the process of caseation necrosis leading to cavity formation in the lung, which supports the statement regarding active TB causing cavitation and tissue destruction.
- name: Drug Resistance Mechanisms
  description: Development of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB through genetic mutations that confer resistance to first-line and second-line antitubercular drugs, driven by ineffective treatment regimens and irregular antibiotic exposure.
  downstream:
  - target: Treatment Failure
    description: Drug-resistant TB strains render standard treatment regimens ineffective, leading to persistent infection and continued disease transmission.
  evidence:
  - reference: PMID:42154079
    reference_title: "Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects."
    supports: SUPPORT
    snippet: There is also a discussion of the MTB lineage and the mutant types. The mechanisms of multidrug resistance and ineffective treatment regimens have driven advances in drug development and alternative therapeutics.
    explanation: This comprehensive review explicitly addresses the mechanisms of multidrug resistance and the role of mutations in driving treatment failures and the need for novel therapeutics.
- name: Immune Evasion
  description: Mycobacterium tuberculosis employs mechanisms of bacterial pathogenesis to counteract the human defense system, contributing to drug resistance and chronic infection persistence.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T Cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: type I interferon signaling pathway
    term:
      id: GO:0060337
      label: type I interferon-mediated signaling pathway
  - preferred_term: adaptive immune response
    term:
      id: GO:0002250
      label: adaptive immune response
  evidence:
  - reference: PMID:42154079
    reference_title: "Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects."
    supports: SUPPORT
    snippet: This comprehensive review introduces the mechanisms of bacterial pathogenesis against the human defence system and the development of drugs against MTB, with particular emphasis on the mechanisms of drug resistance and mutations that render them ineffective globally.
    explanation: This review covers mechanisms by which MTB counteracts the human defense system, supporting pathogen-host immune interactions as a driver of chronic infection.
genetic:
- name: TREM2
  association: Foamy macrophage formation and Mtb persistence
  notes: TREM2-positive macrophages are enriched in alveoli, colocalize with lipid droplets and Mtb antigens, and form permissive niches for bacterial persistence. Mycolic acids and PDIM induce TREM2 expression.
- name: APOE
  association: Lipid metabolism in TB-infected macrophages
  notes: Part of TREM2-positive foamy macrophage signature; mediates lipid trafficking that supports intracellular bacterial niche.
- name: NPC2
  association: Lysosomal cholesterol handling
  notes: Upregulated in foamy macrophages; altered cholesterol transport contributes to lipid droplet accumulation and permissive environment for Mtb.
- name: PLIN2
  association: Lipid droplet marker in foamy macrophages
  notes: Marks lipid droplets that colocalize with Mtb antigens in alveolar macrophages; indicative of metabolic reprogramming.
- name: LIPA
  association: Lysosomal lipid catabolism
  notes: Lysosomal acid lipase involved in cholesterol ester hydrolysis; dysregulated during Mtb infection contributing to foam cell formation.
- name: TBK1
  association: Type I interferon signaling pathway
  notes: Part of cGAS-STING-TBK1-IRF3 cytosolic DNA sensing pathway activated by ESX-1-mediated phagosomal membrane damage.
- name: IRF3
  association: Interferon regulatory transcription factor
  notes: Downstream of TBK1; drives type I interferon responses that can be both protective and pathogenic depending on timing and magnitude.
phenotypes:
- category: Respiratory
  name: Chronic Cough
  description: Persistent cough lasting more than 3 weeks, often productive with sputum, the cardinal respiratory symptom of pulmonary TB.
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:29196066
    reference_title: "Cough Due to TB and Other Chronic Infections: CHEST Guideline and Expert Panel Report."
    supports: PARTIAL
    snippet: Cough is common in pulmonary TB and other chronic respiratory infections.
    explanation: While cough is indeed a common symptom of pulmonary TB, the statement specifically categorizes chronic cough as very frequent, which is partially supported but not explicitly confirmed by the literature.
  - reference: PMID:16131501
    reference_title: "Well defined symptoms are of value in the diagnosis of childhood pulmonary tuberculosis."
    supports: SUPPORT
    snippet: A persistent, non-remitting cough was reported in 15/16 (93.8%) children with tuberculosis.
    explanation: This strongly supports the statement as it shows a high prevalence of a persistent chronic cough in children diagnosed with tuberculosis.
  - reference: PMID:35710915
    reference_title: "Cluster analysis categorizes five phenotypes of pulmonary tuberculosis."
    supports: NO_EVIDENCE
    snippet: Initial microbiologic burdens and radiographic features also varied, including the presence of cavities and bilateral infiltration, which reflect TB-related severity.
    explanation: The study identifies chronic cough as a significant symptomatic characteristic among the different TB phenotypes.
  phenotype_term:
    preferred_term: Chronic Cough
    term:
      id: HP:0034315
      label: Chronic cough
- category: Systemic
  name: Fever
  description: Low-grade fever typically occurring in the afternoon and evening, often accompanied by chills.
  frequency: FREQUENT
  evidence:
  - reference: PMID:11120618
    reference_title: "Tuberculosis as a cause of recurrent fever of unknown origin."
    supports: SUPPORT
    snippet: We describe three patients with recurrent fever thought to be due to tuberculosis, and review the 14 previously reported cases who fulfil the criteria of recurrent fever for at least 1 month's duration
    explanation: The literature indicates that fever is a frequent symptom associated with tuberculosis.
  - reference: PMID:31641790
    reference_title: "[Tuberculosis]."
    supports: PARTIAL
    snippet: Tuberculosis is a bacterial infectious disease that is usually transmitted by inhalation of droplets containing the bacteria.
    explanation: While this reference does affirm that tuberculosis causes systemic issues, it does not directly specify fever as a frequent phenotype.
  - reference: PMID:18173876
    reference_title: "How good are systemic symptoms and blood inflammatory markers at detecting individuals with tuberculosis?"
    supports: PARTIAL
    snippet: 'SETTING: The diagnosis of tuberculosis (TB) may be rejected in the absence of symptoms such as fever, sweats or weight loss.'
    explanation: This reference notes the association of fever with tuberculosis but also highlights cases where fever may be absent, hence only partially supporting the statement.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
- category: Systemic
  name: Night Sweats
  description: Profuse sweating during sleep requiring change of bedclothes, a classic constitutional symptom of active TB.
  frequency: FREQUENT
  evidence:
  - reference: PMID:31599243
    reference_title: "Tuberculosis in Systemic Lupus Erythematosus Patients."
    supports: SUPPORT
    snippet: Cough, night sweat, fever, anorexia were significant presenting features.
    explanation: The study documents night sweats as a significant symptom in TB patients.
  - reference: PMID:12643362
    reference_title: "Diagnosing night sweats."
    supports: PARTIAL
    snippet: Tuberculosis and lymphoma are diseases in which night sweats are a dominant symptom, but these are infrequently found to be the cause of night sweats in modern practice.
    explanation: While night sweats are a notable symptom of TB, the reference suggests that in modern practice, they are less frequently the cause of night sweats compared to other conditions.
  - reference: PMID:21813327
    reference_title: "Clinical symptoms and microbiological outcomes in tuberculosis treatment trials."
    supports: SUPPORT
    snippet: During therapy, fever, sweats, and dyspnea decreased most rapidly, with near resolution by the end of therapy.
    explanation: The data supports the presence of night sweats as a frequent symptom in TB, with sweats reducing significantly during therapy.
  phenotype_term:
    preferred_term: Night sweats
    term:
      id: HP:0030166
      label: Night sweats
- category: Systemic
  name: Weight Loss
  description: Unintentional weight loss and wasting, giving rise to the historical term "consumption" for TB.
  frequency: FREQUENT
  notes: Also known as consumption historically.
  evidence:
  - reference: PMID:36451280
    reference_title: "Predictors of weight loss during the intensive phase of tuberculosis treatment in patients with drug-susceptible pulmonary tuberculosis in South India."
    supports: SUPPORT
    snippet: Tuberculosis (TB) is well-known for causing wasting. Patients on treatment gain weight and weight loss is associated with unfavorable treatment outcomes.
    explanation: This supports the statement that weight loss is a frequently observed systemic phenotype associated with tuberculosis.
  - reference: PMID:38736083
    reference_title: "Challenges in Diagnosis of Esophageal Tuberculosis."
    supports: PARTIAL
    snippet: Esophageal TB most commonly presents with dysphagia, odynophagia, retrosternal pain, and systemic symptoms like decreased appetite, loss of weight, and low-grade fever as associated or other presentations.
    explanation: This reference supports the statement by indicating that weight loss is a common systemic symptom of esophageal tuberculosis.
  - reference: PMID:23531875
    reference_title: "Tuberculosis in CBA/J mice."
    supports: PARTIAL
    snippet: CBA/J mice may model these events, as sick mice share features with TB patients, including weight loss...
    explanation: Although the study is on mice, it draws parallels with human TB patients, reinforcing that weight loss is a frequently observed phenotype.
  - reference: PMID:18173876
    reference_title: "How good are systemic symptoms and blood inflammatory markers at detecting individuals with tuberculosis?"
    supports: PARTIAL
    snippet: The diagnosis of tuberculosis (TB) may be rejected in the absence of symptoms such as fever, sweats or weight loss... In our population, TB, including pulmonary disease, frequently presented without fever, sweats or weight loss and with normal blood inflammatory markers.
    explanation: This indicates that while weight loss is a known symptom, it is not always present in all TB cases, suggesting that it may be frequent but not ubiquitous.
  - reference: PMID:8623687
    reference_title: "Outpatient management of tuberculosis."
    supports: SUPPORT
    snippet: All patients with a positive reaction to the tuberculin skin test should be evaluated for weight loss, night sweats, fever, chronic cough and other signs of active tuberculosis.
    explanation: This reference confirms that weight loss is one of the systemic symptoms that are frequently checked for in TB patients.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Hematologic
  name: Hemoptysis
  description: Coughing up blood or blood-streaked sputum, indicating cavitary disease or erosion into blood vessels.
  frequency: OCCASIONAL
  notes: Coughing up blood.
  evidence:
  - reference: PMID:12816036
    reference_title: "[Hemoptysis]."
    supports: SUPPORT
    snippet: The most common causes of hemoptysis are tuberculosis, lung carcinoma, bronchiectasis but idiopathic forms are frequent.
    explanation: The text states that tuberculosis is one of the most common causes of hemoptysis, supporting the statement.
  phenotype_term:
    preferred_term: Hemoptysis
    term:
      id: HP:0002105
      label: Hemoptysis
- category: Respiratory
  frequency: FREQUENT
  name: Chest Pain
  description: Pleuritic chest pain worsening with breathing or coughing, often indicating pleural involvement.
  notes: Often described as pleuritic chest pain
  evidence:
  - reference: PMID:17508531
    reference_title: "Pleurisy."
    supports: PARTIAL
    snippet: Pleuritic chest pain is a common presenting symptom and has many causes, which range from life-threatening to benign, self-limited conditions.
    explanation: The reference mentions pleuritic chest pain as a common symptom, but it does not specifically state that it is frequently associated with tuberculosis.
  - reference: PMID:27499981
    reference_title: "Tuberculous pleural effusion."
    supports: SUPPORT
    snippet: TPE usually presents as an acute illness with fever, cough and pleuritic chest pain.
    explanation: This reference supports the statement as it explicitly mentions that tuberculous pleural effusion (a form of extrapulmonary tuberculosis) commonly presents with pleuritic chest pain.
  - reference: PMID:30762202
    reference_title: "Chest Tuberculosis in Children."
    supports: NO_EVIDENCE
    snippet: Chest is the commonest site of involvement by tuberculosis (TB) in children; lungs being the most frequently affected region, followed by nodes, pleura and chest wall.
    explanation: While this reference does not directly state chest pain, it supports the involvement of the chest in tuberculosis, which can be associated with pleuritic chest pain.
  - reference: PMID:35809948
    reference_title: "Recurrent Pleuritic Chest Pain, Lobar Consolidation, and Pleural Effusion in a 50-Year-Old Woman."
    supports: NO_EVIDENCE
    snippet: A 50-year-old woman with a history of permanent atrial fibrillation (AF) treated with radiofrequency catheter ablation (RFCA) 6 months ago was admitted to the respiratory department of a tertiary hospital because of recurrent episodes of pleuritic chest pain in the preceding 5 months.
    explanation: This case study mentions recurrent pleuritic chest pain, supporting the statement that chest pain is a frequent symptom in respiratory conditions, including tuberculosis.
  phenotype_term:
    preferred_term: Chest pain
    term:
      id: HP:0100749
      label: Chest pain
- category: Respiratory
  frequency: OCCASIONAL
  name: Dyspnea
  description: Shortness of breath due to extensive pulmonary involvement, pleural effusion, or fibrosis.
  notes: Shortness of breath
  evidence:
  - reference: PMID:15623010
    reference_title: "Tuberculosis prevention and treatment."
    supports: NO_EVIDENCE
    snippet: Symptoms of pulmonary TB are a cough with or without sputum production lasting at least three weeks, chest pain, hemoptysis, fever, night sweats, weight loss, lack of appetite, chills and weakness.
    explanation: The abstract mentions that dyspnea (shortness of breath) is a symptom of pulmonary tuberculosis, which supports the statement that dyspnea is occasionally associated with tuberculosis.
  - reference: PMID:29900887
    reference_title: "Pulmonary functions' assessment in post-tuberculosis cases by spirometry: Obstructive pattern is predominant and needs cautious evaluation in all treated cases irrespective of symptoms."
    supports: PARTIAL
    snippet: Lung function impairment is known to occur after pulmonary TB irrespective of duration of treatment and outcome of disease.
    explanation: This reference indicates that lung function issues, including dyspnea, can persist even after successful treatment of tuberculosis.
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
- category: Systemic
  frequency: OCCASIONAL
  name: Fatigue
  description: Persistent tiredness and weakness associated with chronic infection and inflammatory response.
  evidence:
  - reference: PMID:33645194
    reference_title: "Sarcoidosis Presenting as Fatigue and Weakness."
    supports: NO_EVIDENCE
    snippet: Sarcoidosis is a systemic granulomatous disorder of unknown cause that occurs in both men and women of all races. It typically presents in patients after 20 years of age. Sarcoidosis most frequently involves the lung, but up to 30 percent of patients present with extra-thoracic manifestations. It can involve multiple organs to a variable extent and degree. In areas, where tuberculosis is endemic, the diagnosis of sarcoidosis may be overlooked and misdiagnosed because of clinical and radiographic resemblance.
    explanation: The abstract mentions that tuberculosis can be misdiagnosed as sarcoidosis due to similar symptoms, including fatigue, indicating that fatigue can be a systemic symptom of tuberculosis.
  - reference: PMID:35189895
    reference_title: "How mycobacterium tuberculosis infection could lead to the increasing risks of chronic fatigue syndrome and the potential immunological effects: a population-based retrospective cohort study."
    supports: PARTIAL
    snippet: Patients with chronic fatigue syndrome and post-tuberculosis experience similar symptoms. Furthermore, chronic fatigue syndrome and tuberculosis share similar plasma immunosignatures.
    explanation: The study indicates that tuberculosis can lead to symptoms similar to chronic fatigue syndrome, supporting the statement that fatigue can be a systemic symptom of tuberculosis.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Musculoskeletal
  frequency: OCCASIONAL
  name: Back Pain
  description: Localized spinal pain that may indicate vertebral TB (Pott's disease) with potential neurological complications.
  notes: May indicate spinal tuberculosis (Pott's disease)
  evidence:
  - reference: PMID:16882280
    reference_title: "Spinal tuberculosis: overlooked?"
    supports: SUPPORT
    snippet: The findings of this study indicate that TB is a common cause of LBP that is liable to be overlooked in the differential diagnosis of LBP.
    explanation: The study indicates that tuberculosis is a common cause of low back pain (LBP), supporting the statement that back pain may indicate spinal tuberculosis.
  - reference: PMID:29358061
    reference_title: "Pott's Disease Resulting in Complete Cervical Vertebral Destruction."
    supports: SUPPORT
    snippet: We present a case report of a military veteran presenting with neck pain and initially diagnosed with cervical disc disease. The patient's pain progressed to the point of developing paresthesias in his bilateral upper extremities. Eventually, cervical spine radiographs were obtained that revealed complete cervical vertebral body destruction from spinal tuberculosis.
    explanation: This case report supports the statement that back pain may indicate spinal tuberculosis, as it describes a patient whose neck pain was eventually diagnosed as spinal tuberculosis.
  - reference: PMID:19845697
    reference_title: "Osteoarticular tuberculosis in Tehran, Iran: a 2-year study."
    supports: SUPPORT
    snippet: In TB spondylitis, the lumbar (22.7%) and thoracic (50%) vertebrae were the most commonly involved sites.
    explanation: This study supports the statement by indicating that the lumbar and thoracic vertebrae are commonly involved in TB spondylitis, which can manifest as back pain.
  - reference: PMID:33393654
    reference_title: "Pott disease: when lumbar pain is not innocent."
    supports: SUPPORT
    snippet: In this article, we present a rare case of progressed tuberculous infection involving the respiratory and musculoskeletal system in a 36-year-old patient whose main complaints were non-specific and mild, and started only two weeks before his diagnosis, despite the advanced disease.
    explanation: This case supports the statement by illustrating that tuberculosis can involve the musculoskeletal system, presenting as back pain.
  phenotype_term:
    preferred_term: Back Pain
    term:
      id: HP:0003418
      label: Back pain
- category: Lymphatic
  frequency: OCCASIONAL
  name: Lymphadenopathy
  description: Enlarged lymph nodes, particularly cervical, often cold and matted, indicating extrapulmonary TB.
  notes: Swollen lymph nodes, especially in the neck
  evidence:
  - reference: PMID:30513392
    reference_title: "Tuberculous neck lymphadenopathy: A diagnostic challenge."
    supports: PARTIAL
    snippet: TB can affect most organs in the head and neck region, such as the lymph nodes, larynx, middle ear, oral cavity and pharynx. In particular, as for cervical tuberculosis lymphadenopathy, a predominant involvement of the posterior triangle, supraclavicular, and internal jugular group of nodes bilaterally can be observed.
    explanation: The literature supports that tuberculosis can cause lymphadenopathy, specifically in the neck region, but it does not provide a clear indication of frequency.
  - reference: PMID:38317037
    reference_title: "Lymphoma and Other Lymph Node Pathologies Among Adult Patients with Lymphadenopathy in Abakaliki, Nigeria."
    supports: PARTIAL
    snippet: Other major causes of lymphadenopathy were metastatic tumor deposits, reactive lymphoid hyperplasia, and tuberculous lymphadenitis.
    explanation: The literature indicates that tuberculous lymphadenitis is one of the major causes of lymphadenopathy, but it does not specify how frequently this occurs.
  - reference: PMID:37743370
    reference_title: "Magnitude of tuberculosis lymphadenitis, risk factors, and rifampicin resistance at Adama city, Ethiopia: a cross-sectional study."
    supports: PARTIAL
    snippet: Close to half of patients with enlarged lymph nodes were positive for M. tuberculosis by the GeneXpert method in the study area.
    explanation: The study shows a significant prevalence of TB lymphadenitis among patients with enlarged lymph nodes, but it does not provide a frequency classification such as 'occasional'.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
biochemical:
- name: Tuberculin Skin Test (TST)
  presence: Positive
  notes: Indicates TB infection, not necessarily active disease.
  evidence:
  - reference: PMID:25440529
    reference_title: "Tuberculin skin test positivity without tuberculosis contact: A major challenge in childhood."
    supports: SUPPORT
    snippet: Worldwide, tuberculin skin tests (TSTs) commonly give false positive results for those who had been given the Bacillus-Calmette-Guerin vaccine such as is routinely administered in Turkey.
    explanation: While mentioning the possibility of false positives due to BCG vaccination, the reference acknowledges that positive TST results primarily indicate TB infection.
- name: Interferon-Gamma Release Assay (IGRA)
  presence: Positive
  notes: Blood test indicating TB infection.
  evidence:
  - reference: PMID:28220979
    reference_title: "More significance of TB-IGRA except for the diagnose of tuberculosis."
    supports: SUPPORT
    snippet: TB-IGRA results were in positive proportion to the lymphocytes, CD4(+) T cells and CD4(+) CD28(+) T cells, whereas negative to the Treg cells.
    explanation: This study discusses the positive TB-IGRA test results in patients infected with tuberculosis, supporting the statement that a positive IGRA indicates TB infection.
  - reference: PMID:26018533
    reference_title: "Gamma Interferon Assays Used in the Diagnosis of Tuberculosis."
    supports: SUPPORT
    snippet: Recently, two new diagnostic tests have been introduced; these two new tests can detect TB infection in patients by challenging peripheral blood cells with specific TB proteins.
    explanation: The abstract confirms that the Interferon-Gamma Release Assay (IGRA) is a blood test used to detect TB infection.
  - reference: PMID:33276277
    reference_title: "Optimized interferon-gamma release assays for detection of Mycobacterium bovis infection in African buffaloes (Syncerus caffer)."
    supports: PARTIAL
    snippet: Accurate and early detection of M. bovis infection in buffaloes is important for controlling transmission. Assays that detect cell-mediated immune responses to M. bovis in buffaloes have been developed although these often display suboptimal sensitivity or specificity.
    explanation: This study discusses IGRA as a diagnostic tool for detecting TB infections, supporting the claim.
  - reference: PMID:34049606
    reference_title: "Interferon-gamma release assays for latent tuberculosis infection screening in Canadian federal correctional facilities."
    supports: SUPPORT
    snippet: We observed concordance between TST and QFT-GIT in 90 of 306 (29.4%) inmates. Persons with TST+/QFT-GIT+ results were less likely to be male (OR 3.94, 95% CI 1.73-8.97) or have a BCG vaccination history (OR 0.34, 95% CI 0.12-0.95), and more likely to be foreign-born (P < 0.001).
    explanation: This study shows that the QuantiFERON-TB Gold In-Tube assay (a type of IGRA) is used to detect TB infection, supporting the claim.
  - reference: PMID:34270559
    reference_title: "Mycobacterial heparin-binding hemagglutinin (HBHA)-induced interferon-γ release assay (IGRA) for discrimination of latent and active tuberculosis: A systematic review and meta-analysis."
    supports: SUPPORT
    snippet: The HBHA-IGRA is a promising immunodiagnostic test for discrimination of latent and active TB, which can be added in commercial IGRAs to enhance the differential diagnostic performance.
    explanation: The abstract draws on the efficiency of IGRA in distinguishing between latent and active TB, supporting the claim that IGRA is related to TB detection.
diagnosis:
- name: Sputum Microscopy
  description: Microscopic examination of sputum samples stained with Ziehl-Neelsen or auramine to identify acid-fast bacilli.
  presence: Positive
  notes: Detection of acid-fast bacilli.
  evidence:
  - reference: PMID:30054578
    reference_title: "Automatic microscopic detection of mycobacteria in sputum: a proof-of-concept."
    supports: PARTIAL
    snippet: We developed and evaluated an operator-independent microscopic examination of sputum smears for the automated detection and enumeration of acid-fast bacilli using a ZEISS Axio Scan.Z1 microscope.
    explanation: The study supports that sputum microscopy can detect acid-fast bacilli. It emphasizes an automated method but still aligns with the use of sputum microscopy for diagnosis.
  - reference: PMID:15535337
    reference_title: "Pulmonary tuberculosis--a review of clinical features and diagnosis in 232 cases."
    supports: PARTIAL
    snippet: Sputum direct smear was positive for acid-fast bacilli in only 22.8% of patients and 11.2% were diagnosed base on positive sputum culture
    explanation: This study confirms that sputum microscopy can detect acid-fast bacilli, but it also highlights instances where sputum may be negative even in TB patients.
  - reference: PMID:27847013
    reference_title: "Fluorescein diacetate vital staining for detecting viability of acid-fast bacilli in patients on antituberculosis treatment."
    supports: PARTIAL
    snippet: Of the 100 ZN positive specimens, 74 were FDA positive of which 70 were reported positive by both the readers.
    explanation: Sputum microscopy positivity for acid-fast bacilli is mentioned but the study's focus is on the FDA staining method.
  - reference: PMID:10734523
    reference_title: "Diagnosis of tuberculosis in sputum negative patients in Dar es Salaam."
    supports: PARTIAL
    snippet: Forty three (24.2%) were sputum smear positive for acid fast bacilli (AAFB).
    explanation: The study supports sputum microscopy for TB diagnosis but only in 24.2% of cases verified by smear.
  - reference: PMID:35180496
    reference_title: "Concentrated specimen smear microscopy utilising a polymer membrane sandwich filtration vessel for the detection of acid-fast bacilli in health facilities in Sabah, East Malaysia."
    supports: PARTIAL
    snippet: The SFV-CSSM showed higher sensitivity than DSSM (79.4% versus 60.5%) and less background interference.
    explanation: The study supports sputum microscopy but highlights an advanced method with higher sensitivity.
  - reference: PMID:21333111
    reference_title: "Implementation of liquid culture for tuberculosis diagnosis in a remote setting: lessons learned."
    supports: PARTIAL
    snippet: Although sputum smear microscopy is the primary method for tuberculosis (TB) diagnosis in low-resource settings, it has low sensitivity.
    explanation: Sputum microscopy is acknowledged as the primary method but with limitations in sensitivity.
- name: Chest X-Ray
  description: Radiographic imaging to identify pulmonary infiltrates, cavitations, and hilar lymphadenopathy characteristic of TB.
  notes: Shows cavitary lesions and other signs of active pulmonary TB.
  evidence:
  - reference: PMID:24429302
    reference_title: "Chronic inactive pulmonary tuberculosis and treatment sequelae: chest radiographic features."
    supports: SUPPORT
    snippet: The chest radiograph (CXR) is a key initial tool in the diagnosis of many lung conditions, including pulmonary tuberculosis (TB). With proper use of anti-tuberculosis drugs, TB can be treated effectively and many CXR changes are limited.
    explanation: This reference establishes that chest radiographs (CXRs) are key tools in diagnosing pulmonary tuberculosis, supporting the statement that chest X-ray is used in the diagnosis of TB.
  - reference: PMID:37977833
    reference_title: "Pulmonary tuberculosis presenting with cluster sign and galaxy sign."
    supports: PARTIAL
    snippet: Follow-up CT showed CS progressing to a cavitatory shadow and GS intensification. The detection of Mycobacterium tuberculosis (M. tuberculosis) in a subsequent sputum analysis prompted treatment with antitubercular drugs, leading to symptom relief.
    explanation: This reference supports the statement regarding the use of chest X-rays in diagnosing TB as it discusses how chest CT (an advanced form of X-ray) shows cavitary lesions, which are indicative of active pulmonary TB.
  - reference: PMID:8553964
    reference_title: "Laryngeal tuberculosis: CT findings."
    supports: SUPPORT
    snippet: Radiographic findings consistent with active pulmonary TB were present in all patients.
    explanation: This reference reinforces the use of radiographic imaging (including chest X-rays) in identifying active pulmonary TB.
  - reference: PMID:26634258
    reference_title: "Evaluation of Chest X-ray and Thoracic Computed Tomography in Patients with Suspected Tuberculosis."
    supports: SUPPORT
    snippet: Evaluation for pulmonary TB in children with positive isolated TSTs should be made primarily with PA chest X-ray.
    explanation: This further supports the statement by emphasizing that chest X-rays (PA chest X-ray) are a primary diagnostic tool for evaluating pulmonary TB.
- name: Sputum Culture
  description: Growth of Mycobacterium tuberculosis on solid or liquid media, the gold standard for diagnosis.
  presence: Positive
  notes: Confirms TB diagnosis.
  evidence:
  - reference: PMID:10970761
    reference_title: "Immunologic diagnosis of tuberculosis: a review."
    supports: PARTIAL
    snippet: However, the sensitivity of sputum smear for acid-fast bacteria is only approximately 50% and sputum culture has a relatively long turnaround time.
    explanation: While sputum culture is considered important for TB diagnosis, it has limitations such as long turnaround time which may affect its utility in confirming TB diagnosis promptly.
  - reference: PMID:31666021
    reference_title: "Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure."
    supports: PARTIAL
    snippet: Pulmonary tuberculosis (TB) with detectable Mycobacterium tuberculosis in the sputum is a major source of transmission.
    explanation: Although this article acknowledges the importance of sputum smear for transmission evaluation, it also highlights that viable bacteria may still be present in some 'cured' patients, indicating a limitation in using sputum alone for confirming cure.
  - reference: PMID:32755530
    reference_title: "Molecular detection of Mycobacterium tuberculosis in poor-quality cough specimens."
    supports: SUPPORT
    snippet: Poor-quality cough specimens (n=61) from presumptive tuberculosis cases were cultured and GeneXpert MTB/RIF (Xpert) successfully performed on samples transferred by flocked swab into PrimeStore molecular transport medium (PS-MTM). Mycobacterium tuberculosis was grown in culture from 13 (21.3 %).
    explanation: Supports the idea that sputum culture can confirm TB diagnosis, even from poor-quality specimens.
  - reference: PMID:8758132
    reference_title: "Sputum induction for the diagnosis of tuberculosis."
    supports: SUPPORT
    snippet: Confirmation of tuberculosis in young children is difficult as they seldom expectorate sputum... Mycobacterium tuberculosis was cultured from three of them.
    explanation: Indicates that sputum culture is a useful method for confirming TB diagnosis.
  - reference: PMID:27727131
    reference_title: "Culture is an imperfect and heterogeneous reference standard in pediatric tuberculosis."
    supports: PARTIAL
    snippet: Culture, the accepted reference standard for pediatric TB diagnostics, has a low and variable yield that impacts how diagnostic studies should be reported as well as everyday clinical care.
    explanation: While culture is a standard for pediatric TB diagnostics, the low yield suggests it might not confirm all cases.
  - reference: PMID:34397866
    reference_title: "Comparison of chest computed tomography features between pulmonary tuberculosis patients with culture-positive and culture-negative sputum for non-mycobacteria: A retrospective observational study."
    supports: NO_EVIDENCE
    snippet: Patients with a positive culture for non-mycobacteria were significantly older and had lower levels of physical activity...
    explanation: This study focuses on non-mycobacterial cultures and does not specifically address the role of sputum culture in TB diagnosis.
treatments:
- name: Isoniazid
  description: First-line antibiotic for TB treatment.
  notes: It's important to note that resistance to isoniazid can develop through mutations in the katG gene, which reduces the activation of the drug, or in the inhA gene, which decreases the binding affinity of the activated drug to the InhA enzyme. To minimize the risk of resistance, isoniazid is typically used in combination with other antitubercular drugs, such as rifampicin, ethambutol, and pyrazinamide.
  mechanism:
  - name: Prodrug Activation
    description: Isoniazid is a prodrug that requires activation by the bacterial enzyme catalase-peroxidase (KatG). KatG couples the isonicotinic acyl with NADH to form an isonicotinic acyl-NADH complex.
  - name: Inhibition of InhA
    description: The activated form of isoniazid binds to and inhibits the enoyl-acyl carrier protein reductase (InhA), an enzyme involved in the fatty acid synthase II (FAS-II) pathway. This pathway is essential for the synthesis of mycolic acids.
  - name: Depletion of mycolic acids
    description: By inhibiting InhA, isoniazid prevents the synthesis of mycolic acids, which are long-chain fatty acids that make up a significant portion of the mycobacterial cell wall. Mycolic acids provide structural integrity and help the bacteria resist the host's immune response.
  - name: Cell wall disruption
    description: The depletion of mycolic acids leads to the weakening and disruption of the bacterial cell wall. This makes the bacteria more susceptible to the host's immune defenses and other antibiotics.
  - name: Reactive oxygen species
    description: In addition to inhibiting mycolic acid synthesis, the isoniazid-NAD adduct can also generate reactive oxygen species (ROS) and nitric oxide (NO) within the bacteria. These reactive species can cause damage to various bacterial components, including DNA, proteins, and lipids, contributing to the bactericidal effect.
  - name: Bactericidal action
    description: The combination of cell wall disruption and the production of reactive oxygen and nitrogen species ultimately leads to the death of the M. tuberculosis bacteria.
  evidence:
  - reference: PMID:33106268
    reference_title: "Acetylation of Isoniazid Is a Novel Mechanism of Isoniazid Resistance in Mycobacterium tuberculosis."
    supports: SUPPORT
    snippet: Isoniazid (INH), one of the first-line drugs used for the treatment of tuberculosis, is a prodrug which is activated by the intracellular KatG enzyme of Mycobacterium tuberculosis.
    explanation: The description of Isoniazid as a first-line antibiotic for TB treatment and its activation by the KatG enzyme is supported. This aligns with the provided mechanism of prodrug activation.
  - reference: PMID:12164478
    reference_title: "Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis."
    supports: SUPPORT
    snippet: The drugs shown to inhibit mycolic acid biosynthesis are isoniazid, ethionamide, isoxyl, thiolactomycin, and triclosan.
    explanation: The inhibition of mycolic acid biosynthesis by Isoniazid aligns with the described mechanism of action in the statement.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: isoniazid
      term:
        id: CHEBI:6030
        label: isoniazide
- name: Rifampicin
  description: Bactericidal antibiotic used for TB treatment.
  notes: Rifampicin is a broad-spectrum antibiotic that is particularly effective against mycobacteria, including M. tuberculosis, as it can easily penetrate the lipid-rich cell wall.
  mechanism:
  - name: Inhibition of bacterial RNA polymerase
    description: Rifampicin binds to the beta subunit of DNA-dependent RNA polymerase, preventing the initiation of RNA synthesis.
  - name: Disruption of bacterial transcription
    description: By inhibiting RNA polymerase, rifampicin disrupts bacterial transcription, which is essential for protein synthesis and bacterial survival.
  evidence:
  - reference: PMID:11290327
    reference_title: "Structural mechanism for rifampicin inhibition of bacterial rna polymerase."
    supports: SUPPORT
    snippet: Rifampicin (Rif) is one of the most potent and broad spectrum antibiotics against bacterial pathogens and is a key component of anti-tuberculosis therapy, stemming from its inhibition of the bacterial RNA polymerase (RNAP).
    explanation: This reference explains that Rifampicin is a key component of anti-tuberculosis therapy due to its inhibition of bacterial RNA polymerase.
  - reference: PMID:27553018
    reference_title: "Tuberculosis and its Treatment: An Overview."
    supports: SUPPORT
    snippet: For the treatment of TB, administration of multiple antibiotics such as isoniazid, rifampicin, pyrazinamide, and ethambutol is required for a long period of time to kill bacteria.
    explanation: This reference confirms that rifampicin is used for the treatment of TB.
  - reference: PMID:34400805
    reference_title: "Rifamycin antibiotics and the mechanisms of their failure."
    supports: SUPPORT
    snippet: Rifamycins exhibit bactericidal activity against many Gram-positive and Gram-negative bacteria by inhibiting RNA polymerase (RNAP).
    explanation: This reference supports the statement by confirming that Rifamycins, including rifampicin, exhibit bactericidal activity by inhibiting RNA polymerase.
  - reference: PMID:33199626
    reference_title: "The antibiotic sorangicin A inhibits promoter DNA unwinding in a Mycobacterium tuberculosis rifampicin-resistant RNA polymerase."
    supports: SUPPORT
    snippet: Rif targets the enzyme RNA polymerase (RNAP).
    explanation: This reference affirms the mechanism of rifampicin targeting RNA polymerase, which validates its use in TB treatment.
  - reference: PMID:28803492
    reference_title: "Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?"
    supports: SUPPORT
    snippet: Rifamycin antibiotics, like rifampin and rifapentine, have unique sterilizing activity against M.tb.
    explanation: This reference supports the use of rifampicin (a Rifamycin antibiotic) for TB treatment due to its sterilizing activity against Mycobacterium tuberculosis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rifampicin
      term:
        id: CHEBI:28077
        label: rifampicin
- name: Ethambutol
  description: Bacteriostatic antibiotic used for TB treatment.
  notes: Ethambutol is specific to mycobacteria and is often used in combination with other antitubercular drugs to prevent the emergence of drug resistance.
  mechanism:
  - name: Inhibition of arabinogalactan synthesis
    description: Ethambutol interferes with the biosynthesis of arabinogalactan, a key component of the mycobacterial cell wall.
  - name: Inhibition of arabinosyl transferase
    description: Ethambutol inhibits the enzyme arabinosyl transferase, which is responsible for the polymerization of arabinose into arabinan, a precursor of arabinogalactan.
  - name: Compromised cell wall integrity
    description: By disrupting the synthesis of arabinogalactan, ethambutol compromises the integrity of the cell wall, making the bacteria more susceptible to host defenses and other antibiotics.
  evidence:
  - reference: PMID:16209089
    reference_title: "The effect of ethambutol on mycobacterial cell wall permeability to hydrophobic compounds."
    supports: SUPPORT
    snippet: Ethambutol (EMB), the first line drug in the treatment of tuberculosis, is an inhibitor of the biosynthesis of the cell wall compound - arabinogalactan.
    explanation: The literature states that ethambutol interferes with the biosynthesis of arabinogalactan, supporting the mechanism described in the statement.
  - reference: PMID:9949810
    reference_title: "Mechanisms for isoniazid action and resistance."
    supports: PARTIAL
    snippet: Isoniazid is the most widely used antituberculosis drug.
    explanation: The statement specifies ethambutol as a bacteriostatic antibiotic used for TB treatment, whereas this reference talks about isoniazid. It is partially relevant since ethambutol is also an antituberculosis drug, but this reference does not fully address ethambutol's function.
  - reference: PMID:37289062
    reference_title: "Wollamide Cyclic Hexapeptides Synergize with Established and New Tuberculosis Antibiotics in Targeting Mycobacterium tuberculosis."
    supports: SUPPORT
    snippet: In combination with TB antibiotics, wollamide B1 synergistically enhances the activity of several antibiotics... and wollamide B1 did not compromise the antimycobacterial activity of the isoniazid/rifampicin/ethambutol combination.
    explanation: This reference confirms that ethambutol is used in combination with other antitubercular drugs, aligning with the notes in the statement about preventing the emergence of drug resistance.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ethambutol
      term:
        id: CHEBI:4877
        label: ethambutol
- name: Directly Observed Therapy (DOT)
  description: Health worker observes and records patients taking their medication to ensure adherence.
  evidence:
  - reference: PMID:17943789
    reference_title: "Directly observed therapy for treating tuberculosis."
    supports: SUPPORT
    snippet: Directly observed therapy (DOT), which involves people directly observing patients taking their antituberculous drugs.
    explanation: The abstract clearly states that DOT involves someone directly observing patients taking their antituberculous drugs to ensure adherence.
  - reference: PMID:29461901
    reference_title: "Predicting treatment outcome of drug-susceptible tuberculosis patients using machine-learning models."
    supports: SUPPORT
    snippet: The World Health Organization (WHO) propagates Directly Observed Therapy Short-course (DOTS) as an effective way to stop the spread of TB in communities with a high burden.
    explanation: The abstract indicates that DOTS is endorsed by WHO as a method to ensure patients adhere to TB treatment.
  - reference: PMID:28410705
    reference_title: "Patients' perception towards directly observed treatment - A qualitative study from Kollam district, Kerala, southern India."
    supports: SUPPORT
    snippet: A flexible, patient centered approach were a family member can act as the DOT provider with guidance from a trained health worker was evolved as the most acceptable and comfortable mode of treatment to majority of the TB patients
    explanation: The abstract reinforces the involvement of a health worker in observing DOT, even if it's flexible to involve family members.
  - reference: PMID:27598709
    reference_title: "A New Method to Directly Observe Tuberculosis Treatment: Skype Observed Therapy, a Patient-Centered Approach."
    supports: SUPPORT
    snippet: To best ensure compliance, directly observed therapy (DOT) is considered the standard of practice.
    explanation: Emphasizes DOT as a standard practice to ensure compliance by observing the patient directly.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Latent TB Treatment
  description: Isoniazid or rifapentine used to prevent latent TB from becoming active.
  evidence:
  - reference: PMID:29910114
    reference_title: "Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis."
    supports: SUPPORT
    snippet: The 3-month isoniazid-rifapentine regimen is as safe and effective as other recommended latent tuberculosis infection regimens and achieves significantly higher treatment completion rates.
    explanation: This source supports the statement mentioning that a regimen of isoniazid and rifapentine is used for latent TB infection.
  - reference: PMID:19496388
    reference_title: "Identification and management of latent tuberculosis infection."
    supports: SUPPORT
    snippet: The treatment of choice for LTBI is isoniazid for nine months.
    explanation: This source supports the use of isoniazid for the prevention of latent tuberculosis infection (LTBI).
  - reference: PMID:32551948
    reference_title: "Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis."
    supports: SUPPORT
    snippet: The World Health Organization recommends the use of isoniazid (INH) alone or in combination with rifapentine to treat latent tuberculosis infections.
    explanation: This supports the statement by specifying that WHO recommends isoniazid and rifapentine for the treatment of latent tuberculosis infections.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Host-Directed Therapy
  description: Adjunctive strategies to enhance autophagy, modulate inflammasome activity, or reprogram macrophage lipid metabolism alongside standard antibiotics.
  notes: Emerging therapeutic approaches include autophagy inducers, anti-inflammatory agents targeting excessive NET formation or inflammasome activation, and lipid metabolism modulators to limit foamy macrophage formation and bacterial persistence.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: SQ109
  description: Ethylenediamine compound derived from ethambutol pharmacophore development that targets MmpL3 (mycobacterial membrane protein Large 3), a trehalose monomycolate flippase required for mycobacterial cell wall biosynthesis, with activity against drug-resistant TB strains.
  notes: Emerging compound exploring new pharmacological targets against M. tuberculosis. Chemically distinct from bedaquiline (a diarylquinoline) — SQ109 is N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: SQ109
      term:
        id: CHEBI:188155
        label: SQ109(1+)
  evidence:
  - reference: PMID:42154079
    reference_title: "Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects."
    supports: SUPPORT
    snippet: New molecules that can potentially disarm MTB have been explored, including SQ109, GuaB2, Q203, Largazole, and Auranofin.
    explanation: Novel compound identified as having potential to address MTB drug resistance.
- name: GuaB2
  description: Inhibitor of inosine 5'-monophosphate dehydrogenase (IMPDH, encoded by guaB2) in M. tuberculosis, a validated drug target essential for guanine nucleotide biosynthesis.
  notes: Emerging target-based therapeutic explored for activity against MTB.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42154079
    reference_title: "Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects."
    supports: SUPPORT
    snippet: New molecules that can potentially disarm MTB have been explored, including SQ109, GuaB2, Q203, Largazole, and Auranofin.
    explanation: Novel compound identified as having potential to address MTB drug resistance.
- name: Q203
  description: Emerging TB drug (telacebec) targeting the cytochrome bc1 complex (QcrB subunit) of the mycobacterial respiratory chain, with activity against multidrug-resistant and extensively drug-resistant TB.
  notes: Novel agent with mechanism distinct from traditional first-line drugs.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42154079
    reference_title: "Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects."
    supports: SUPPORT
    snippet: New molecules that can potentially disarm MTB have been explored, including SQ109, GuaB2, Q203, Largazole, and Auranofin.
    explanation: Novel compound identified as having potential to address MTB drug resistance.
- name: Largazole
  description: Cyclodepsipeptide natural product (histone deacetylase inhibitor) with potential antimycobacterial activity being explored as a novel TB therapeutic.
  notes: Natural product-derived compound in development for TB treatment.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: largazole
      term:
        id: CHEBI:212400
        label: Largazole
  evidence:
  - reference: PMID:42154079
    reference_title: "Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects."
    supports: SUPPORT
    snippet: New molecules that can potentially disarm MTB have been explored, including SQ109, GuaB2, Q203, Largazole, and Auranofin.
    explanation: Novel compound identified as having potential to address MTB drug resistance.
- name: Auranofin
  description: Gold-containing compound (originally approved for rheumatoid arthritis) with antimycobacterial activity through thioredoxin reductase inhibition, being repurposed for TB treatment, particularly in drug-resistant cases.
  notes: Emerging therapeutic option with novel chemical composition.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: auranofin
      term:
        id: CHEBI:2922
        label: auranofin
  evidence:
  - reference: PMID:42154079
    reference_title: "Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects."
    supports: SUPPORT
    snippet: New molecules that can potentially disarm MTB have been explored, including SQ109, GuaB2, Q203, Largazole, and Auranofin.
    explanation: Novel compound identified as having potential to address MTB drug resistance.
- name: Natural Compound Therapy
  description: Exploration of natural compounds as adjunctive or alternative approaches for TB treatment.
  notes: Includes plant-derived and natural product-based therapeutic strategies.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42154079
    reference_title: "Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects."
    supports: SUPPORT
    snippet: natural compounds, bacteriophage therapy, antimicrobial peptides, and probiotics are also explored to help address the global threat posed by MTB.
    explanation: Emerging therapeutic modalities beyond conventional antibiotics being evaluated for TB treatment.
- name: Bacteriophage Therapy
  description: Use of bacteriophages (viruses that infect bacteria) as alternative antimicrobial agents against M. tuberculosis.
  notes: Emerging biotechnology approach for potential TB treatment, particularly relevant for drug-resistant strains.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42154079
    reference_title: "Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects."
    supports: SUPPORT
    snippet: natural compounds, bacteriophage therapy, antimicrobial peptides, and probiotics are also explored to help address the global threat posed by MTB.
    explanation: Emerging therapeutic modality being investigated to combat MTB and address antibiotic resistance.
- name: Antimicrobial Peptide Therapy
  description: Use of synthetic or naturally-derived peptides with antimicrobial properties against M. tuberculosis.
  notes: Emerging immunotherapeutic approach leveraging host defense mechanisms.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42154079
    reference_title: "Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects."
    supports: SUPPORT
    snippet: natural compounds, bacteriophage therapy, antimicrobial peptides, and probiotics are also explored to help address the global threat posed by MTB.
    explanation: Emerging therapeutic modality being investigated to combat MTB and address antibiotic resistance.
- name: Probiotic Therapy
  description: Use of beneficial microorganisms to enhance immune function and support conventional TB treatment.
  notes: Emerging host-directed therapeutic approach.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:42154079
    reference_title: "Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects."
    supports: SUPPORT
    snippet: natural compounds, bacteriophage therapy, antimicrobial peptides, and probiotics are also explored to help address the global threat posed by MTB.
    explanation: Emerging therapeutic modality being investigated to combat MTB and address antibiotic resistance.
clinical_trials:
- name: NCT03568383
  phase: PHASE_III
  description: Open-label randomized prophylaxis study comparing delamanid versus isoniazid for preventing active tuberculosis among high-risk household contacts of adults with multidrug-resistant TB over 96 weeks of follow-up.
  evidence:
  - reference: clinicaltrials:NCT03568383
    supports: SUPPORT
    snippet: "The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with multidrug-resistant tuberculosis (MDR-TB) (index cases)."
    explanation: This trial evaluates delamanid as preventive therapy for household contacts of MDR-TB patients, directly relevant to tuberculosis control strategies.
notes: TB is a significant global health issue, particularly in low-income and developing countries.
disease_term:
  preferred_term: tuberculosis
  term:
    id: MONDO:0018076
    label: tuberculosis
📚

References & Deep Research

Deep Research

2
Disorder ▸

Disorder

  • Name: Tuberculosis
  • Category: Infectious Disease
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 109

Key Pathophysiology Nodes

  • Phagocytosis
  • Granuloma Formation
  • Neutrophil Activation and NETosis
  • Tissue Damage
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1016/j.celrep.2024.115072
  • DOI:10.1101/2025.07.15.664002
  • DOI:10.1128/spectrum.01188-24
  • DOI:10.3389/fimmu.2023.1305325
  • DOI:10.3389/fimmu.2024.1402024
  • DOI:10.3390/ijms25158196
Falcon ▸
Pathophysiology Description
Edison Scientific Literature 19 citations 2025-12-15T10:10:08.032076

Pathophysiology Description Mycobacterium tuberculosis (Mtb) subverts innate immune defenses through specialized secretion systems, metabolic reprogramming of host phagocytes, and induction of maladaptive inflammatory programs. Type VII secretion, especially ESX-1, promotes phagosomal membrane damage and cytosolic access, which triggers cytosolic DNA sensing through cGAS–STING–TBK1 and induction of type I interferon (IFN) programs; ESX effectors can concomitantly inhibit autophagy and impair phagosome maturation, facilitating intracellular survival (jiang2024mycobacteriumtuberculosisvii pages 1-2). Metabolic rewiring of macrophage cholesterol handling fuels foamy macrophage formation and creates nutrient-rich, permissive niches (chen2024theimpactof pages 1-2). In the lung, spatial single-cell and spatial-transcriptomic profiling indicates distinct microenvironments: alveolar regions harbor TREM2+ foamy macrophages enriched for lipid handling genes and Mtb antigens, whereas granuloma cores exhibit interferon-driven antimicrobial signatures (teles2025spatialprofilingreveals pages 5-8, teles2025spatialprofilingreveals pages 8-11). Neutrophils contribute importantly to immunopathology; type I IFN–linked neutrophil programs and neutrophil extracellular traps (NETs) correlate with tissue damage and relapse risk, positioning NET-associated pathways as potential host-directed therapy (HDT) targets (saqib2025pathogenicrolefor pages 26-27). Inflammasome pathways (e.g., NLRP3/AIM2→caspase-1→IL‑1β) have context-dependent roles in early control versus pathology and are actionable in HDT concepts (cebani2024canweexploit pages 1-2).

Key Concepts and Definitions with Current Understanding - Type VII secretion (ESX-1): A specialized secretion system that exports virulence substrates (e.g., EsxA/ESAT‑6 and EsxB/CFP‑10) to permeabilize the phagosomal membrane, enabling cytosolic access and engagement of host DNA sensors (jiang2024mycobacteriumtuberculosisvii pages 1-2). - Cytosolic DNA sensing (cGAS–STING–TBK1): Host pathway that detects bacterial DNA in the cytosol and induces type I IFN responses; in TB, activation can both promote antimicrobial programs and drive detrimental inflammation depending on timing and magnitude (jiang2024mycobacteriumtuberculosisvii pages 1-2). - Foamy macrophages: Lipid droplet–rich macrophages formed through increased cholesterol uptake/synthesis and impaired efflux, supporting Mtb persistence and TB progression (chen2024theimpactof pages 1-2). In human TB lungs, a TREM2+ foamy macrophage program is spatially concentrated in alveoli (teles2025spatialprofilingreveals pages 5-8, teles2025spatialprofilingreveals pages 8-11). - NETosis/NETs: Neutrophil extracellular traps contribute to TB tissue pathology (caseating granulomas, vascular occlusion) and may be driven by IFN-linked programs; restraining NET formation can improve outcomes in relevant models (saqib2025pathogenicrolefor pages 26-27). - Inflammasomes: Canonical (e.g., NLRP3, AIM2) and non-canonical (caspase‑4/5/11) complexes mature IL‑1β/IL‑18 and drive pyroptosis; balanced modulation is a candidate HDT strategy in TB (cebani2024canweexploit pages 1-2).

Recent Developments and Latest Research (2023–2024 priority) - ESX effector Rv2347c/EsxP: “Rv2347c … inhibits the expression of the early marker RAB5 of phagosomes … triggers the host’s cytoplasmic sensing pathway STING/TBK1, inhibiting autophagy and upregulating IFNβ transcription” (Microbiology Spectrum, Nov 2024; DOI: 10.1128/spectrum.01188-24) (jiang2024mycobacteriumtuberculosisvii pages 1-2). - Macrophage cholesterol metabolism: Mtb increases LDL uptake and de novo cholesterol synthesis, suppresses cholesterol ester hydrolysis and ABC-transporter–mediated efflux, driving lipid droplet accumulation and foam cell formation that facilitates persistence and granuloma/cavitation (Frontiers in Immunology, May 2024; DOI: 10.3389/fimmu.2024.1402024) (chen2024theimpactof pages 1-2). - Spatial single-cell mapping in human TB: Alveoli/pneumonia regions contain TREM2+ foamy macrophages enriched for lipid metabolism (APOE, LIPA, NPC2, PLIN2), while granuloma cores show IFN-activated macrophages and higher expression of antimicrobial genes; TREM2 colocalizes with lipid droplets and Mtb antigens (bioRxiv, Aug 2025; DOI: 10.1101/2025.07.15.664002) (teles2025spatialprofilingreveals pages 5-8, teles2025spatialprofilingreveals pages 8-11). - Neutrophil pathogenic programs: Type I IFN–linked neutrophil responses drive lung inflammation, NETosis, and pathology; specific neutrophil subsets (e.g., CD101‑negative) and NET-associated mechanisms are implicated as targets (Cell Reports, Jan 2025; DOI: 10.1016/j.celrep.2024.115072) (saqib2025pathogenicrolefor pages 26-27). - Inflammasome HDT concepts: Reviews detail priming (TLRs→NF‑κB), activation (NLRP3/AIM2), caspase‑1/11/4/5, gasdermin D, and IL‑1 family maturation as targets for precision modulation in TB (IJMS, Jul 2024; DOI: 10.3390/ijms25158196) (cebani2024canweexploit pages 1-2).

Current Applications and Real‑World Implementations - Pathway-informed HDTs: Reviews emphasize adjunctive HDTs to enhance autophagy, temper excessive inflammasome activity, or reprogram macrophage lipid metabolism alongside antibiotics, including repurposed drugs and small molecules (Frontiers in Immunology, Jan 2024; DOI: 10.3389/fimmu.2023.1305325) (zhao2024hostdirectedtherapyagainst pages 14-14). Translational implications also extend to NET inhibition strategies where excessive NETosis drives tissue injury (saqib2025pathogenicrolefor pages 26-27). - Spatially guided targets: Spatial profiling highlights distinct compartments (alveoli versus granuloma core) and cell states (TREM2+ foamy versus IFN-activated macrophages), guiding localized or state-specific interventions (teles2025spatialprofilingreveals pages 5-8, teles2025spatialprofilingreveals pages 8-11).

Expert Opinions and Analysis from Authoritative Sources - ESX-1 as central virulence hub: The 2024 Microbiology Spectrum study and related literature converge on ESX-1 as a driver of phagosomal rupture and downstream type I IFN induction, with specific effectors (e.g., EsxP) also inhibiting autophagy—an actionable axis for antivirulence or HDT strategies (jiang2024mycobacteriumtuberculosisvii pages 1-2). - Lipid metabolism as a therapeutic node: The 2024 Frontiers in Immunology review argues that reducing host cholesterol availability or restoring efflux can limit Mtb invasion and enhance antibiotic efficacy—offering a rational HDT direction (chen2024theimpactof pages 1-2). - Compartmentalized pathophysiology: Spatial single-cell work reveals alveoli enriched in lipid‑handling macrophages harboring Mtb antigens, versus granuloma cores with IFN‑driven antimicrobial programs—supporting tailored interventions by lesion context (teles2025spatialprofilingreveals pages 5-8, teles2025spatialprofilingreveals pages 8-11). - NETs as double-edged swords: Neutrophil/NET programs are repeatedly implicated in advanced disease; strategies that limit NETosis (e.g., PAD4 inhibition) without broadly suppressing host defense merit investigation (saqib2025pathogenicrolefor pages 26-27). - Inflammasome balance: Reviews stress that both insufficient and excessive inflammasome activity are harmful, advocating precision modulation rather than wholesale suppression (cebani2024canweexploit pages 1-2).

Relevant Statistics and Data from Recent Studies - Spatial single-cell atlas (human pulmonary TB): 45,023 single cells profiled (avg. ~1,017 genes/cell), 27 cell types (10 myeloid, 7 lymphocyte); TREM2+ foamy macrophages localized to alveoli; granuloma cores with higher antimicrobial gene expression (e.g., 15 genes significantly higher vs alveoli, adjusted p = 3.72×10⁻⁷) (bioRxiv, Aug 2025; DOI: 10.1101/2025.07.15.664002) (teles2025spatialprofilingreveals pages 5-8). - TREM2 induction by mycobacterial lipids: Mycolic acids and PDIM induced ~50–55% TREM2+ macrophages in vitro; live Mtb induced ~30% TREM2+ cells; TREM2–DAP12 reporter correlated with activation (r=0.93, p=0.007) (bioRxiv, Aug 2025; DOI: 10.1101/2025.07.15.664002) (teles2025spatialprofilingreveals pages 8-11).

Core Pathophysiology - Primary mechanisms: ESX-1–mediated phagosome damage and cytosolic translocation; cGAS–STING–TBK1–IRF3 activation and type I IFN responses; autophagy inhibition by ESX effectors; host lipid metabolic reprogramming→foamy macrophages; neutrophil activation and NETosis; compartmentalized lesion biology (jiang2024mycobacteriumtuberculosisvii pages 1-2, chen2024theimpactof pages 1-2, teles2025spatialprofilingreveals pages 5-8, saqib2025pathogenicrolefor pages 26-27). - Dysregulated pathways: Type I IFN signaling, autophagy, cholesterol uptake/efflux and ester metabolism, inflammasome activation (jiang2024mycobacteriumtuberculosisvii pages 1-2, chen2024theimpactof pages 1-2, cebani2024canweexploit pages 1-2). - Affected cellular processes: Phagosome maturation/lysosome fusion, xenophagy/autophagy flux, lipid droplet biogenesis, NET formation, IFN-stimulated gene programs (jiang2024mycobacteriumtuberculosisvii pages 1-2, chen2024theimpactof pages 1-2, saqib2025pathogenicrolefor pages 26-27).

Key Molecular Players - Genes/Proteins: EsxA/EsxB (ESX-1), Rv2347c/EsxP, cGAS, STING, TBK1, IRF3, IFN‑β, TREM2, APOE, NPC2, PLIN2, LIPA, ABC transporters (ABCA1/ABCG1 class), IL‑1β (jiang2024mycobacteriumtuberculosisvii pages 1-2, chen2024theimpactof pages 1-2, teles2025spatialprofilingreveals pages 5-8, cebani2024canweexploit pages 1-2). - Chemical entities: Cholesterol (ChEBI:28694); interferon‑β; NET-modulatory agents (e.g., PAD4 inhibitors) as conceptual HDTs (chen2024theimpactof pages 1-2, saqib2025pathogenicrolefor pages 26-27). - Cell types: Macrophages (alveolar, TREM2+ foamy, IFN-activated), neutrophils, Th17 cells, dendritic cells (teles2025spatialprofilingreveals pages 5-8, saqib2025pathogenicrolefor pages 26-27). - Anatomical locations: Alveoli/pneumonia regions versus granuloma cores/mantles (teles2025spatialprofilingreveals pages 5-8).

Biological Processes (GO) for Annotation - Type I interferon signaling (GO:0034138): cGAS–STING–TBK1–IRF3–IFNβ axis following ESX-1–mediated cytosolic access (jiang2024mycobacteriumtuberculosisvii pages 1-2). - Autophagy/xenophagy (GO:0006914): Targeted and inhibited by ESX effectors; HDT target (jiang2024mycobacteriumtuberculosisvii pages 1-2). - Lipid metabolic process (GO:0006629): Cholesterol uptake/synthesis, esterification and impaired efflux leading to foamy macrophages (chen2024theimpactof pages 1-2). - Cholesterol transport (GO:0030301): ABC transporter–mediated efflux is suppressed during infection (chen2024theimpactof pages 1-2). - Neutrophil degranulation/NET formation (GO:0043312): Contributes to tissue injury and relapse risk (saqib2025pathogenicrolefor pages 26-27). - Inflammasome complex assembly and IL‑1β maturation: Context-dependent protective/pathologic roles; HDT node (cebani2024canweexploit pages 1-2).

Cellular Components - Phagosome and phagolysosome membranes; cytosol (site of cGAS–STING sensing after ESX-mediated rupture) (jiang2024mycobacteriumtuberculosisvii pages 1-2). - Lipid droplets (PLIN2+) and lysosomes (NPC2/LIPA) in foamy macrophages (teles2025spatialprofilingreveals pages 5-8, chen2024theimpactof pages 1-2). - Extracellular region (NETs); inflammasome complexes (cytosolic) (saqib2025pathogenicrolefor pages 26-27, cebani2024canweexploit pages 1-2).

Disease Progression (sequence of events) - Inhalation and alveolar deposition → uptake by alveolar macrophages → ESX-1–mediated phagosome damage and cytosolic access → cGAS–STING–TBK1–IRF3 activation and type I IFN programs; autophagy inhibition by ESX effectors (e.g., EsxP) → metabolic rewiring of macrophages to lipid-laden, TREM2+ foamy states in alveoli → lesion heterogeneity with granuloma cores enriched for IFN‑activated antimicrobial signatures and neutrophil influx/NETs in progressive disease → cavitation and dissemination in advanced disease (jiang2024mycobacteriumtuberculosisvii pages 1-2, chen2024theimpactof pages 1-2, teles2025spatialprofilingreveals pages 5-8, saqib2025pathogenicrolefor pages 26-27).

Phenotypic Manifestations (mechanism–phenotype links) - Caseating necrosis and tissue destruction: Associated with neutrophil-driven inflammation and NETosis; vascular occlusions with neutrophil aggregates reported in TB (mechanistic framework; NETs) (saqib2025pathogenicrolefor pages 26-27). - Alveolar pneumonia with macrophage lipid accumulation: TREM2+ foamy macrophages colocalize with Mtb antigens and lipid droplets in alveoli (teles2025spatialprofilingreveals pages 5-8, teles2025spatialprofilingreveals pages 8-11). - Granuloma core IFN bias: IFN-driven antimicrobial gene expression and IFN-activated macrophage states correspond to granuloma cores (teles2025spatialprofilingreveals pages 5-8).

Evidence Items with URLs and Publication Dates - Jiang et al., 2024 (Microbiology Spectrum, Nov 2024): “Rv2347c … blocks the maturation of phagosomes … activates the STING/TBK1 signaling pathway to inhibit cell autophagy” (DOI: 10.1128/spectrum.01188-24; https://doi.org/10.1128/spectrum.01188-24) (jiang2024mycobacteriumtuberculosisvii pages 1-2). - Chen et al., 2024 (Frontiers in Immunology, May 30, 2024): “Mtb infection increases the uptake of LDL and cholesterol … suppresses ABC transporters … promoting the formation of lipid droplets and foam cells” (DOI: 10.3389/fimmu.2024.1402024; https://doi.org/10.3389/fimmu.2024.1402024) (chen2024theimpactof pages 1-2). - Teles et al., 2025 preprint (bioRxiv, Aug 2025): Spatial profiling of human TB lungs identifies TREM2+ foamy macrophages in alveoli and IFN-activated programs in granuloma cores; TREM2 colocalizes with PLIN2 and Mtb antigens; mycolic acids/PDIM induce ~50–55% TREM2+ macrophages (DOI: 10.1101/2025.07.15.664002; https://doi.org/10.1101/2025.07.15.664002) (teles2025spatialprofilingreveals pages 5-8, teles2025spatialprofilingreveals pages 8-11). - Saqib et al., 2025 (Cell Reports, Jan 2025): Type I IFN–mediated neutrophil programs drive immunopathology and NETosis; NETs implicated in TB tissue damage and as therapeutic targets (DOI: 10.1016/j.celrep.2024.115072; https://doi.org/10.1016/j.celrep.2024.115072) (saqib2025pathogenicrolefor pages 26-27). - Cebani & Mvubu, 2024 (International Journal of Molecular Sciences, Jul 2024): Inflammasome pathways (NLRP3/AIM2→caspase‑1→IL‑1β; non‑canonical caspase‑4/5/11) as HDT targets in TB (DOI: 10.3390/ijms25158196; https://doi.org/10.3390/ijms25158196) (cebani2024canweexploit pages 1-2). - Zhao et al., 2024 (Frontiers in Immunology, Jan 2024): Review of HDT strategies for TB and TB–diabetes comorbidity, including autophagy promotion and immunomodulation (DOI: 10.3389/fimmu.2023.1305325; https://doi.org/10.3389/fimmu.2023.1305325) (zhao2024hostdirectedtherapyagainst pages 14-14).

Structured, Ontology-Linked Annotations | Category | Entity (identifier) | Role in TB | Key Process/Pathway (GO) | Cellular Component (GO/CC) | Cell Type (CL) | Anatomical Site (UBERON) | Chemical/Drug (ChEBI) | Evidence | |---|---|---|---|---|---|---|---|---| | Secretion system | ESX-1 (Type VII secretion system) | Mediates phagosomal membrane permeabilization and secretion of ESX substrates that enable cytosolic access and immune modulation | secretion / phagosomal membrane permeabilization (ESX-1 function) | bacterial secretion apparatus / phagosome membrane | infected macrophage (CL:0000235) | alveolus of lung (UBERON:0008952) | — | Microbiology Spectrum doi:10.1128/spectrum.01188-24; Nov 2024 (jiang2024mycobacteriumtuberculosisvii pages 1-2) | | Effector proteins | EsxA / EsxB (ESAT-6 / CFP-10) | Pore-forming effectors that contribute to phagosomal rupture and downstream host sensing | (ESX-1 substrate secretion) | phagosomal membrane / pore complex | macrophage (CL:0000235) | phagosome / cytosol (lung) | — | Microbiology Spectrum doi:10.1128/spectrum.01188-24; Nov 2024 (jiang2024mycobacteriumtuberculosisvii pages 1-2) | | Effector protein | Rv2347c / EsxP (Rv2347c) | Blocks phagosome maturation, promotes phagosome escape → activates STING/TBK1 → ↑IFN-β and inhibits autophagy | GO:0034138 type I interferon signaling pathway; GO:0006914 autophagy (inhibition) | phagosome / cytosol; STING-associated membranes | macrophage (CL:0000235) | alveolus of lung (UBERON:0008952) | — | Microbiology Spectrum doi:10.1128/spectrum.01188-24; Nov 2024 (jiang2024mycobacteriumtuberculosisvii pages 1-2) | | Cytosolic DNA sensor axis | cGAS–STING–TBK1–IRF3 → IFN-β | Cytosolic DNA sensing of escaped Mtb triggers type I IFN responses that can be host-protective or pathologic depending on timing/amount | GO:0034138 type I interferon signaling pathway | cytosol; ER-Golgi/ STING localization | macrophage (CL:0000235), dendritic cell | lung parenchyma / granuloma core | interferon-β (ChEBI:interferon-β) | Microbiology Spectrum doi:10.1128/spectrum.01188-24; Nov 2024; Cell Reports summary (jiang2024mycobacteriumtuberculosisvii pages 1-2, saqib2025pathogenicrolefor pages 26-27) | | Autophagy | Host autophagy (xenophagy) | Autophagy is inhibited by ESX effectors (promotes Mtb survival); restoration is an HDT target | GO:0006914 autophagy | autophagosome / lysosome (GO:0005764) | macrophage (CL:0000235) | intracellular compartment (lung) | mTOR inhibitors / autophagy inducers (e.g., rapamycin) | Microbiology Spectrum doi:10.1128/spectrum.01188-24; Nov 2024 (jiang2024mycobacteriumtuberculosisvii pages 1-2) | | Lipid uptake receptor | CD36 (CD36) | Scavenger receptor mediating uptake of lipids/cholesterol → supports foamy macrophage phenotype that favours Mtb persistence | GO:0006629 lipid metabolic process | plasma membrane; endocytic vesicles | macrophage (CL:0000235) | alveolus of lung (UBERON:0008952) | cholesterol (ChEBI:28694) | Frontiers in Immunology doi:10.3389/fimmu.2024.1402024; May 2024 (chen2024theimpactof pages 1-2) | | Lipid handling protein | APOE (apolipoprotein E) | Mediates lipid trafficking; part of TREM2+/foamy macrophage signature and linked to permissive intracellular niche | GO:0006629 lipid metabolic process | lipid particles / extracellular region | macrophage (CL:0000235) | alveolar space (UBERON:0008952) | cholesterol / apolipoproteins (ChEBI:28694) | Spatial/transcriptomic data (TREM2+ program) doi:10.1101/2025.07.15.664002; Aug 2025 (teles2025spatialprofilingreveals pages 5-8) | | Intracellular lipid transporter | NPC2 (NPC2) | Lysosomal cholesterol handling; part of foamy macrophage / lipid-droplet program associated with permissive Mtb niches | GO:0030301 cholesterol transport | lysosome / lipid droplet | macrophage (CL:0000235) | alveolus / macrophage lipid droplet | cholesterol (ChEBI:28694) | Spatial/transcriptomic data doi:10.1101/2025.07.15.664002; Aug 2025 (teles2025spatialprofilingreveals pages 5-8) | | Lipid droplet marker | PLIN2 (perilipin-2) | Marks lipid droplets / foamy macrophages that harbor Mtb antigens; indicates altered host lipid storage | GO:0006629 lipid metabolic process | lipid droplet (GO:0005811) | macrophage (CL:0000235) | alveoli / pneumonia regions (UBERON:0008952) | neutral lipids (ChEBI:5891) | Spatial/transcriptomic data doi:10.1101/2025.07.15.664002; Aug 2025 (teles2025spatialprofilingreveals pages 5-8) | | Lipase / lipid catabolism | LIPA (lysosomal acid lipase) | Lysosomal hydrolysis of cholesteryl esters / triglycerides; dysregulated in infected macrophages | GO:0006631 fatty acid metabolic process | lysosome | macrophage (CL:0000235) | alveolus / phagolysosome | cholesterol esters (ChEBI:??) | Frontiers in Immunology doi:10.3389/fimmu.2024.1402024; May 2024 (chen2024theimpactof pages 1-2) | | Cholesterol efflux | ABC transporters (e.g., ABCA1/ABCG1) | Reduced expression during Mtb infection → impaired cholesterol efflux → foam cell formation | GO:0030301 cholesterol transport | plasma membrane / lipid raft | macrophage (CL:0000235) | alveolus / lung | cholesterol (ChEBI:28694) | Frontiers in Immunology doi:10.3389/fimmu.2024.1402024; May 2024 (chen2024theimpactof pages 1-2) | | Macrophage subset | TREM2+ foamy macrophages | Lipid-laden, permissive macrophage population concentrated in alveoli; colocalize with Mtb antigens and lipid droplets | GO:0006629 lipid metabolic process | lipid droplets; phagolysosome | macrophage (CL:0000235; TREM2+ subset) | alveolus of lung (UBERON:0008952) | — | Spatial/transcriptomic & proteomics doi:10.1101/2025.07.15.664002; Aug 2025 (teles2025spatialprofilingreveals pages 5-8) | | Neutrophil effector structures | NETs (MPO, neutrophil elastase; PAD4-dependent) | NETosis characterizes caseating granulomas; contributes to tissue damage, immunothrombosis and relapse risk | GO:0043312 neutrophil degranulation / NET formation | extracellular traps (extracellular region) | neutrophil (CL:0000775) | granuloma core / pulmonary vessels | PAD4 inhibitors (e.g., Cl-amidine) | Cell Reports / review summaries doi:10.1016/j.celrep.2024.115072; Jan 2025 (saqib2025pathogenicrolefor pages 26-27) | | Inflammasome pathway | NLRP3 / AIM2 → caspase-1 → IL-1β | Canonical inflammasomes mature IL-1β/IL-18 and drive pyroptosis; dual role (control vs tissue damage); candidate HDT targets | (inflammasome activation; IL-1β maturation) | inflammasome complex (cytosol) | macrophage / DC (CL:0000235; CL:0001056) | granuloma / lung | IL-1β (ChEBI:17052) | Int J Mol Sci doi:10.3390/ijms25158196; Jul 2024 (cebani2024canweexploit pages 1-2) | | Spatial compartments | Alveoli (pneumonia) vs granuloma core (lesion) | Distinct programs: alveoli enriched for lipid metabolism/foamy macrophages; granuloma core enriched for IFN-driven antimicrobial programs and SPP1+/IFN-activated macrophages | alveoli: lipid metabolism (GO:0006629); core: type I/II IFN & antimicrobial responses (GO:0034138) | alveolar lumen vs granuloma core | alveolar macrophage (CL:0000235); IFN-activated macrophage | alveolus of lung (UBERON:0008952); granulomatous lesion (region) | — | Spatial single-cell & ROI profiling doi:10.1101/2025.07.15.664002; Aug 2025 (teles2025spatialprofilingreveals pages 5-8) | | Host-directed therapy (HDT) targets | HDT (autophagy inducers, lipid modulators, inflammasome modulators) | Therapeutic strategies to restore autophagy, limit pathological inflammation, or reprogram macrophage lipid handling | autophagy promotion; inflammasome modulation; metabolic reprogramming | various (autophagosome, inflammasome) | macrophage, neutrophil, DC | lung / systemic | candidate drugs cited in reviews (repurposed agents) | Frontiers in Immunology (HDT review) doi:10.3389/fimmu.2023.1305325; Jan 2024 (zhao2024hostdirectedtherapyagainst pages 14-14) |

Table: Concise ontology-ready annotations linking key TB mechanisms, genes/proteins, cell types, compartments, and candidate chemicals with source DOIs and context IDs; useful for knowledge‑base ingestion and evidence-traced curation.

Abbreviations and Ontologies - HGNC: TREM2, APOE, NPC2, PLIN2, LIPA, CD36, TBK1, IRF3, IL1B. - GO: GO:0034138 (type I IFN signaling); GO:0006914 (autophagy); GO:0006629 (lipid metabolism); GO:0030301 (cholesterol transport); GO:0043312 (neutrophil degranulation/NET formation). - CL: CL:0000235 (macrophage); CL:0000775 (neutrophil). - UBERON: UBERON:0008952 (alveolus of lung). - CHEBI: CHEBI:28694 (cholesterol).

Limitations and Open Questions - Although type I IFN signatures and NETs are implicated in pathogenesis, the precise windows where IFN or NET modulation improves clinical outcomes remain to be defined in humans (saqib2025pathogenicrolefor pages 26-27). - Spatial single-cell findings are compelling but include preprint data; further peer-reviewed validation and integration with clinical phenotypes are needed (teles2025spatialprofilingreveals pages 5-8, teles2025spatialprofilingreveals pages 8-11).

Overall, contemporary evidence supports a model in which ESX-1–driven cytosolic access and cGAS–STING activation, macrophage lipid reprogramming to TREM2+ foamy states, and type I IFN–linked neutrophil/NET programs collectively drive TB progression, while inflammasome and autophagy pathways offer promising HDT entry points (jiang2024mycobacteriumtuberculosisvii pages 1-2, chen2024theimpactof pages 1-2, teles2025spatialprofilingreveals pages 5-8, saqib2025pathogenicrolefor pages 26-27, cebani2024canweexploit pages 1-2, zhao2024hostdirectedtherapyagainst pages 14-14).

References

  1. (jiang2024mycobacteriumtuberculosisvii pages 1-2): Zhiyong Jiang, Junfeng Zhen, Yuerigu Abulikena, Chaoyun Gao, Lingxi Huang, Tingting Huang, and Jianping Xie. mycobacterium tuberculosis vii secretion system effector molecule rv2347c blocks the maturation of phagosomes and activates the sting/tbk1 signaling pathway to inhibit cell autophagy. Microbiology Spectrum, Nov 2024. URL: https://doi.org/10.1128/spectrum.01188-24, doi:10.1128/spectrum.01188-24. This article has 8 citations and is from a domain leading peer-reviewed journal.

  2. (chen2024theimpactof pages 1-2): Zhanpeng Chen, Xingxing Kong, Quan Ma, Jinyun Chen, Yuqin Zeng, Huazhen Liu, Xiaomin Wang, and Shuihua Lu. The impact of mycobacterium tuberculosis on the macrophage cholesterol metabolism pathway. Frontiers in Immunology, May 2024. URL: https://doi.org/10.3389/fimmu.2024.1402024, doi:10.3389/fimmu.2024.1402024. This article has 19 citations and is from a peer-reviewed journal.

  3. (teles2025spatialprofilingreveals pages 5-8): Rosane M. B. Teles, Chaouki Benabdessalem, Jonathan Perrie, Cenfu Wei, Julie West, Bruno J. de Andrade Silva, Priscila R. Andrade, Lilah A. Mansky, Prajan Divakar, Linda Fischbacher, Karen Lam, Feiyang Ma, Kimia Rategh, Aparna Pillai, Samuel M. French, Emna Romdhane, Mohamed-Ridha Barbouche, Eynav Klechevsky, Marco Colonna, Adrie J. C. Steyn, Steven J. Bensinger, Daniel L. Barber, Soumaya Rammeh, Parambir S. Dulai, Bryan D. Bryson, Matteo Pellegrini, John T. Belisle, Barry R. Bloom, and Robert L. Modlin. Spatial profiling reveals trem2+ macrophages as central to mycobacterium tuberculosis pathogenesis in human pulmonary tuberculosis. bioRxiv : the preprint server for biology, Aug 2025. URL: https://doi.org/10.1101/2025.07.15.664002, doi:10.1101/2025.07.15.664002. This article has 0 citations.

  4. (teles2025spatialprofilingreveals pages 8-11): Rosane M. B. Teles, Chaouki Benabdessalem, Jonathan Perrie, Cenfu Wei, Julie West, Bruno J. de Andrade Silva, Priscila R. Andrade, Lilah A. Mansky, Prajan Divakar, Linda Fischbacher, Karen Lam, Feiyang Ma, Kimia Rategh, Aparna Pillai, Samuel M. French, Emna Romdhane, Mohamed-Ridha Barbouche, Eynav Klechevsky, Marco Colonna, Adrie J. C. Steyn, Steven J. Bensinger, Daniel L. Barber, Soumaya Rammeh, Parambir S. Dulai, Bryan D. Bryson, Matteo Pellegrini, John T. Belisle, Barry R. Bloom, and Robert L. Modlin. Spatial profiling reveals trem2+ macrophages as central to mycobacterium tuberculosis pathogenesis in human pulmonary tuberculosis. bioRxiv : the preprint server for biology, Aug 2025. URL: https://doi.org/10.1101/2025.07.15.664002, doi:10.1101/2025.07.15.664002. This article has 0 citations.

  5. (saqib2025pathogenicrolefor pages 26-27): Mohd Saqib, Shreya Das, Tanvir N. Nafiz, Elizabeth McDonough, Poornima Sankar, Lokesh K. Mishra, Ximeng Zhang, Yi Cai, Selvakumar Subbian, and Bibhuti B. Mishra. Pathogenic role for cd101-negative neutrophils in the type i interferon-mediated immunopathogenesis of tuberculosis. Cell Reports, 44:115072, Jan 2025. URL: https://doi.org/10.1016/j.celrep.2024.115072, doi:10.1016/j.celrep.2024.115072. This article has 16 citations and is from a highest quality peer-reviewed journal.

  6. (cebani2024canweexploit pages 1-2): Lilitha Cebani and Nontobeko E. Mvubu. Can we exploit inflammasomes for host-directed therapy in the fight against mycobacterium tuberculosis infection? International Journal of Molecular Sciences, 25:8196, Jul 2024. URL: https://doi.org/10.3390/ijms25158196, doi:10.3390/ijms25158196. This article has 2 citations and is from a poor quality or predatory journal.

  7. (zhao2024hostdirectedtherapyagainst pages 14-14): Li Zhao, Ke Fan, Xuezhi Sun, Wei Li, Fenfen Qin, Liwen Shi, Feng Gao, and Chunlan Zheng. Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus. Frontiers in Immunology, Jan 2024. URL: https://doi.org/10.3389/fimmu.2023.1305325, doi:10.3389/fimmu.2023.1305325. This article has 13 citations and is from a peer-reviewed journal.